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1
I N T R O D U C T I O N
"Et profecto non hic mihi tempero quin gratulabundus
animadvertertam, DEUM Omnipotentem, ..., non aliud
remedium quod vel pluribus malis debellandis par sit, vel
eadem efficacius extirpet, humano generi in miseriarum
solamen concessisse, quam sunt opiata [...]."
Thomas Sydenham (1624-1689) [1, p. 174]
1.1 opium , opiates , and opioids
taxonomy and general principles Parts and products of
the opium poppy (Papaver somniferum) have been used for many
centuries as a remedy to cure all kinds of disorders. The exact point
in time when it was first used as a drug and/or remedy is not entirely
agreed upon, but literature suggests the use of opium in ancient times
already [2]. As the opening quote shows, English doctor and scientist
Thomas Sydenham in 1680 reflected on the importance of opiates ap-
proximately as follows:
"And indeed I shall not hesitate to complimentingly declare here that it
pleased Almighty God to bestow upon mankind in its suffering a remedy
unlike any other in its versatility and efficacy, and that is opium."
The dried latex from the opium poppy is referred to as opium. It
contains a variety of alkaloids, of which morphine, codein, thebaine,
papaverine, and noscapine are of the most pharmaceutical relevance
[3]. The alkaloids are contained in the latex to various extents. They
are used as drugs themselves or serve as the basis for further modi-
fied substances. The terminus opiate is not used uniformly in the liter-
ature. It can either refer only to alkaloids actually contained in natural
opium (like the aforementioned) or also include semi-synthetic drugs,
which are derived from the natural alkaloids [4]. Opioids is used as
the generic term for all opiates or opiate-derived analgesic substances,
including fully synthetic opioid drugs. This very basic classification
is, among others, also used to categorize opioid drugs.
opioids in this work The opioids used in this work group into
the mentioned categories as follows (references to structural formulae
in the appendix):
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• Opium alkaloids (figure 29)
Morphine is the one opium alkaloid used in this work. Al-
though it can be chemically synthesized completely [5], it is
usually extracted from the poppy plant for economic reasons.
morphine-6-glucuronide (M-6-G) is is the main metabolite of
morphine in the human organism.
• Semi-synthetic alkaloid derivatives (figure 30)
– Buprenorphine is synthesized from the opium alkaloid
thebaine [6]. It acts as a mixed partial agonist / antago-
nist at various opioid receptors. As such, it has nanomolar
affinities for the µ, κ, δ, and nociceptin receptor, with in-
trisic activity only at the µ and nociceptin receptor [7].
– Hydromorphone is synthesized from native morphine [8]
and generally has similar properties as its parent substance.
– Oxycodone is another thebaine derivative [9, 10] with con-
firmed µ-opioid receptor (µ receptor) and disputed κ re-
ceptor affinities [11].
• Synthetic opioids
– Anilidopiperidines (figure 31)
∗ Fentanyl is a high-affinity, high-potency µ receptor
ligand [12]. Like several other neurotropic drugs, it
was first synthesized by Paul Janssen [13].
∗ Remifentanil is a high-affinity, highly potent, and ultra-
short acting opioid analgesic [14]. It is distinct from all
the others in so far as it is degraded by unspecific es-
terases rather rather than organ-specific metabolic sys-
tems.
∗ Sufentanil [15] is the most potent opioid used in hu-
mans.
– Diphenylpropylamine derivatives (figure 32)
∗ Piritramide was first synthesized by Janssen [16] and
is approved for use in patients only in certain Euro-
pean countries, including Germany.
∗ Methadone is a potent µ receptor activator. It occurs
in R- and S-enantiomeric form. The opioid analgesic
effects are mostly attributed to R-methadone (Levo-
methadone), whereas the racemate is said to also show
N-methyl-D-aspartate (NMDA) receptor activity [17].
– Phenylpiperidines (figure 33)
∗ Pethidine is also one of the early opioids [18], but in
many countries including the U.S. is not in use any-
more. This is due to its undesired effects, which are
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mainly caused by the neurotoxic metabolite norpethi-
dine [19].
– Others (chemically less similar to the other opioids, but
with distinct µ receptor affinity, figure 34)
∗ Tilidine was described in 1970 by Herrmann et al.
[20]. It is metabolized rapidly, therefore its effects are
mainly mediated by (1S,2R)-tilidine (dextilidine) and
metabolites thereof [21]. Tilidine is used medically only
in a few countries, including Germany, where it comes
as a fixed combination with the µ receptor antagonist
naloxone.
∗ Tramadol is a µ receptor agonist [22], but also acts
on various other receptors/neurotransmitter systems:
serotonin release and reuptake inhibition [23, 24], nore-
pinephrine reuptake inhibition [25], NMDA antagonism
[26], and more. Tramadol is used as a racemate of the
(1R,2R)- and (1S,2S)-isomers, since it turned out to be
more effective in humans than either enantiomer alone
[27].
∗ Tapentadol has been developed only recently and,
like Tramadol, has norepinephrine reuptake inhibition
properities in addition to being an opioid analgesic
[28].
• Synthetic peptides (figure 35) All the endogenous ligands of opi-
oid recpetors are peptides. [D-Ala2, N-MePhe4, Gly-ol]-en-
kephalin (DAMGO) is a synthetic, µ receptor-specific peptide
agonist [29]. It is widely used as a reference compound in the
literature.
effects and undesired side-effects Opioids to this day still
represent the gold standard in the treatment of mild to severe cancer
pain [32, 33]. Morphine, methadone, and codeine are in the WHO’s
Model List of Essential Medicines [34]. In a clinical context, opioids
are often characterized as weak or strong opioids, with a relative ob-
served potency normalized to the morphine effect. Also, pharmacoki-
netics of opioids differ substantially and need to be taken into consid-
eration. The opioids used in this work range from relative potencies
of 1/10 (tramadol, tapentadol) to ∼1,000 (sufentanil) [35] (for details,
see table 1). The indication for the use of opioids in pain other than
tumor-related is rather weak. Some authors doubt the usefulness of
opioids in non-cancer pain [36–38]. Eventually, a recent Cochrane re-
view found opioids to be effective also in non-cancer pain patients
[39].
Much of the concern with the broad usage of opioids originates
from their wide range of undesired side-effects. First and foremost,
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opioid relative potency
DAMGO n/a (synthetic peptide)
Buprenorphine 25
Fentanyl 100
Hydromorphone 5
Methadone 1
Morphine 1
M-6-G n/a (no approved drug)
Naloxone n/a (antagonist)
Naltrexone n/a (antagonist)
Oxycodone 1
Pethidine 0.1
Piritramide 0.7
Remifentanil 300
Sufentanil 1,000
Tapentadol [30] 0.33-0.5∗
Tilidine 0.1
Tramadol 0.1
Table 1: Clinical potencies of opioids used in this work relative to morphine.
Adapted from Graefe et al. [31]. ∗ Data from animal testing; no data
from randomized clinical trials available.
tolerance to the analgesic effects is often observed in patients and
leads to dose escalation which in turn can cause additional undesired
effects to occur [40]. Among those are sedation, dizziness, nausea,
vomiting, constipation, physical dependence, tolerance, and respira-
tory depression [41]. Respiratory depression certainly poses the most
severe threat to patients and, although it is relatively rare, it can be
treatment-limiting [42]. Yet still, in 2007 unintentional lethal opioid
overdoses were estimated at nearly 12,000 in the United States [43].
Constipation occurs markedly more often and has substantial influ-
ence on quality of life [44]. As such, obstipation is a major reason for
patients to discontinue opioid therapy [45]. When it comes to recre-
ational use, the United Nations Office on Drugs and Crime estimated
the number of global illicit opioid users at around 30 million, or 0.6-
0.8 % global prevalence (out of 5.2% total prevalence of all illegal
drug use) in 2013 [46]. But also within legal boundaries, opioid use
is high: there were 238 million prescriptions of opioid analgesics in
2011 in the United States alone [47].
1.2 the signalome of g protein-coupled receptors 5
1.2 the signalome of g protein-coupled receptors
G protein-coupled receptors (GPCRs) are a superfamily of membrane
receptors, whose members are characterized by (1) seven helices span-
ning the cell membrane (seven-transmembrane domain receptors) and
(2) at the same time binding to so called G proteins (guanosine nucleo-
tide-binding proteins) as their main effector molecules. This super-
family comprises more than 800 receptors in the human genome,
of which around 350 to 400 are functional non-olfactory receptors
[48, 49]. Of those, another 140 are so called orphan receptors [50], i.e.
no specific transmitter has yet been found for these receptors. Still,
GPCRs are the largest entity of established drug targets so far [51].
More than half of the prescription medicines worldwide directly tar-
get GPCRs [52].
g protein-coupled receptors The idea of receptors as a con-
cept probably dates back to 1905, when Langley [53], while working
on nervous stimulation, hypothesized the existence of a "receptive
substance", which should be "capable of affecting the metabolism".
However, at that time this idea was more than controversial. It was
not until the 1970s, when work from the laboratory of R. Lefkowitz
could show the existence of α-adrenergic [54] and β-adrenergic [55]
receptors by means of the then modern method of radioligand bind-
ing. This continued work eventually culminated in the Nobel Prize in
Chemistry awarded to Robert Lefkowitz and Brian Kobilka in 2012
for their work on GPCRs [56].
There are several classification systems in place to bring order into
the plethora of GPCRs. Commonly, GPCRs are grouped into six classes
based on genetic sequence and function as follows [57]:
• Class A: Rhodopsin-like receptor family
• Class B: Secretin receptor family
• Class C: Metabotropic glutamate receptor family
• Class D and E receptors are not found in humans
• Class F: Frizzeled/smoothened receptor family
The rhodopsin family represents the largest of all families, which
are in turn grouped into several subfamilies. A more recent phylo-
genetic approach to GPCR-classification established the GRAFS (glu-
tamate, rhodopsin, adhesion, frizzled/taste2, secretion) families [48].
The µ receptor, on which this work mainly focuses, belongs to class
A of GPCRs (or the rhodopsin familiy, respectively).
structural and functional properties of gpcrs In all
GPCRs, the N-terminus lies on the extracellular side of the plasma
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Figure 1: Cartoon rendering of a 2.8 Å resolution crystal structure of a
murine µ receptor (class A) [58]. It shows the seven helical TMs
in rainbow colors, with intra- and extracellular loops connecting
the helices. The receptor is oriented with its extracellular parts fac-
ing up. Image rendered using PyMol from PDB ID 4DKL.
membrane. The linear protein then spans the membrane seven times,
therefore there are three intracellular loops (ICLs) and three extracellu-
lar loops (ECLs). The C-terminus of the receptor is inside the cell. An
exemplary GPCR structure is shown in figure 1.
Ligand binding is facilitated in most class A receptors by equiva-
lent residues in TMs 3, 6, and 7 forming the ligand-binding pocket.
Variations in this region of the receptor are thought to be responsible
for ligand specificity. Binding of a ligand to the receptor and, thus,
receptor activation leads to several conformational changes, mainly
small changes to the distortion of TM5, relocation of TM3 and TM7,
and rotation of TM5 and TM6 [59]. In general, these processes are
nowadays thought to occur in a stochastic rather than a determinis-
tic manner, i.e. active, inactive, and intermediate conformations exist
throughout; ligand binding merely moves the equilibrium towards
the active conformation. Furthermore, the presence of an agonist is
believed to "increase structural heterogeneity in ... cytoplasmatic do-
mains", thereby enabling binding of the G protein [60]. After all, com-
plete activation of the receptor requires a G protein. The activation of
a GPCR after ligand binding occurs rapidly (e.g. 40 ms for the α2A
adrenergic receptor; 1 s for the parathyroid hormone receptor [61]).
g proteins G proteins are a family of signal transduction pro-
teins. Their immediate biochemical function is that of a GTPase and
they are activated by GPCRs. A G protein is considered active when
guanosine triphosphate (GTP) is bound and inactive when guanosine
diphosphate (GDP) is bound. G proteins exist in two major classes:
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monomeric, "small" G proteins and heterotrimeric, "large" G proteins.
The latter consist of three different subunits denoted as α, β, and
γ [62]. The γ subunit bears the actual GTPase activity. The β and
γ subunits usually form a stable dimeric complex. The former are
monomeric GTPases, analogous to the α subunit of heterotrimeric G
proteins. They were not of primary interest in this work. A trimeric
Gs protein bound to the β2-adrenergic recptor is shown in figure 2.
When a GPCR is activated by an agonistic ligand, it binds a G
protein and by that causes conformational change therein. The change
in conformation allows for the GDP bound to the α subunit of the so
far inactive G protein to be exchanged for a GTP, thus activating the G
protein [63]. Whether this activation of the G protein manifests merely
in relative movement of the subunits against each other or whether
the α subunit and the βγ complex dissociate is subject to ongoing
debate [64, 65]. The activated G protein facilitates further signalling
into the inside of the cell until its intrinsic GTPase activity hydrolizes
the GTP to a GDP, thereby reconstituting the original state.
Several subtypes of G protein subunits exist, whereas the type of
the α subunit is primarily responsible for immediate further signaling.
The principal Gα subunit families are:
• Gαi family
• Gs family
• Gq family and
• G12/13 family
The Gαi family consists of various subtypes, most importantly Gαi1−3
and Gα0. Gαt or transducin is the respective Gα protein subunit of
the rhodopsin receptor [66]. The i stands for inhibitory, because most
members of the Gαi family inhibit an enzyme called adenocyclase,
which produces cyclic adenosine monophosphate (cAMP) [67]. cAMP
is an important second messenger, causing, among others, elevated
Ca2+ levels in the cytosol.
There are two major members of the Gαs family: Gαs and Gαol f , the
latter coupling to olfactory receptors. Both activate adenylyl cyclases,
resulting in increased levels of cAMP. Accordingly, the s stands for
stimulating.
The Gαq family mainly consists of Gαq and Gα11, although the sub-
types 14, 15, and 16 have been described to belong to this family, too.
Their main function is to couple the receptor to an enzyme called
phospholipase C (PLC) [68]. PLC cleaves phosphatidylinositol 4,5-
bisphosphate into diacyl gylcerol and inositol 1,4,5-trisphosphate, both
of which are signaling effectors in the cell.
One major effect of Gα12/13 proteins is the activation of GTPases of
the Rho family [69].
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The Gβγ complex can be made up of a variety of β and γ sub-
types. There seems to be no selectivity of certain α subtypes for spe-
cific βγ combinations. However, certain combinations of βγ subunits
were shown to influence the extent of G protein activation by the α2A
adrenergic receptor [70]. The βγ complex works and occurs only as
a dimer [71] and has two main functions. First, it acts as a negative
modulator of the α subunit. When in the heterotrimer (or when the G
protein is inactive, that is), it increases the affinity of Gα for GDP, thus
stabilizing the inactive form [72]. Second, the βγ complex functions
as a signaling molecule itself: it can regulate ion channels [73, 74] or
interfere with adenylyl cyclases [75] as some α subunits do.
Many GPCRs can couple to more than one Gα subtype. For each
receptor there is distinct selectivity for the types of G proteins it cou-
ples to. However, the mechanistics of this selectivity are poorly un-
derstood so far. The interaction between receptor and G protein is
fast. Förster resonance energy transfer (FRET) studies with the α2A
adrenergic receptor and Gi showed interaction kinetics faster than
100 ms [76]. The activation of the G protein itself, i.e. the conforma-
tional change it undergoes, was found to take place within 400-500
ms for the same receptor and G protein [76].
Figure 2: Cartoon rendering of a 3.2 Å crystal structure of the β2-AR-Gs
complex [77]. blue: receptor, red: Gα, yellow: Gβ, green: Gγ. Image
rendered from PDB ID 3SN6 and adapted using PyMol.
arrestins Arrestins are, next to G proteins, another family of pro-
teins known to interact directly with GPCRs. Currently, there are four
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known arrestins. The first one was found in 1986 by Wilden et al.
[78] as a protein which deactivated signaling of the rhodopsin recep-
tor. The second arrestin was first described by Lohse et al. [79] and
termed β-arrestin (β-arr), because they found it to interact with the
β2-AR. By that time it was not clear that indeed arrestin 2 would inter-
act with hundreds of GPCRs. Current terminology lists arrestins 1-4,
where arrestins 1 and 4 are the so-called visual arrestins. Arrestins 2
and 3 are the ones interacting with many of the known GPCRs. In the
literature they are commonly referred to as β-arrestin 1 and β-arrestin
2, respectively, which is prone to cause some confusion. Particularly
β-arr 1 and 2, but all four arrestins in general, show high structural
homology. In this work, the interaction of β-arrs 1 and 2 (i.e. arrestins
2 and 3) with the µ receptor was under investigation.
The function of β-arrs which was described initially is the promo-
tion of receptor internalization [80]. Herein, β-arr links the receptor to
clathrin [81], the clathrin adaptor AP2 [82], and several more proteins
which eventually lead to the formation of a vesicle containing the
receptor via so called clathrin-coated pits [83]. Moreover, after acti-
vation of a GPCR (and phosphorylation thereof, see next paragraph),
β-arr binds with high affinity to the receptor and as a consequence ter-
minates receptor signaling to the cell by sterically preventing further
G protein coupling to the receptor [83]. Further direct interaction part-
ners of β-arr are, among others, components of the mitogen-activated
protein kinases (MAPK) pathway [84]. It was shown that β-arr inter-
acts simultaneously with ERK, MEK1, and Raf, all of which form a
signaling complex activating several transcription factors in the nu-
cleus [85]. Often, β-arr1 and β-arr2 serve similar purposes within a
cell, however β-arr2 has higher affinity for class A GPCRs [86], to
which also the µ receptor belongs.
g protein-coupled receptor kinases G protein-coupled re-
ceptor kinases (GRKs) are a family of serine/threonine kinases, which
phosphorylate residues at the intracellular C-terminal end and the
third intracellular loop of GPCRs [87]. The family comprises seven
members to this date (GRKs 1-7) [88, 89]. Expression of GRK1 (retina
[52]), GRK4 (testes [90]) and GRK7 (retina [89]) is restricted to certain
tissues, the other GRKs are expressed ubiquitously in humans. GRKs
are grouped into three subfamilies by distinct features: GRK1 and 7
are the retinal kinases; GRKs2 and 3 contain a C-terminal pleckstrin
homology domain and are recruited to the cell membrane dependent
on binding to the βγ subunit of a G protein; GRK5 and 6 are per-
manently associated with the plasma membrane [87]. Three distinct
functional domains can be found in a GRK. (1) The N-terminal re-
gion contains an RH (RGS homology) domain. RGS stands for regu-
lator of G protein signaling, i.e. these domains can bind to Gα subunits
and deactivate them. However, this has so far only been described
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for GRKs 2 and 3 [91]. (2) The central part of a GRK holds the cat-
alytic domain for its kinase activity [83]. (3) The C terminal regions
of GRKs vary. All GRKs bear some form sub-cellular targeting motif
at this site, mostly via lipid binding to the cell membrane. As pointed
out, GRK2 and 3 hold a C-terminal PH domain, which is responsible
for the recruitment of the GRK to the receptor via interaction with
the βγ subunit of the already bound G protein. Yet it was shown
that the pleckstrin homology domain of GRKs2 and 3 also attenuates
Gβγ signaling via sequestration of the molecule [92], much like the
N-terminal RH domain does with distinct Gα subunits.
Apart from GPCR phosporylation, GRKs are known to interact
with a plethora of other molecules. Studies showed many non-GPCR
molecules to be substrates of certain GRKs, as well as a variety of
phosphorylation-independent interactions (review: [93]).
At the µ receptor there are around 20 potential phosphorylation
sites at intracellular parts of the receptor [94]. Both GRK2 and 3 were
shown to contribute to receptor phosphorylation in vitro [95, 96].
The investigation of their respective contributions to phosphoryla-
tion and β-arr recruitment is complicated by the fact that only GRK3-
but not GRK2-knockout mice are viable [97]. Nonetheless, studies us-
ing phosphorylation-specific antibodies continue to shed light on the
matter. Ser375 turned out to be of particular importance for β-arr re-
cruitment and consequent receptor internalization [98, 99] along with
Thr376 and Ser379 [100]. Moreover, these studies also showed that
low-efficacy agonists (especially morphine) are a lot less effective in
inducing phosphorylation than high-efficacy agonists (e.g. DAMGO).
This is compatible with findings that the function of GRK2 (and 3)
relies on the βγ subunits of activated G proteins. As a consequence,
morphine is a very weak inducer of receptor internalization in recom-
binant expression systems, yet this ability can be enhanced markedly
by overexpression of GRK2 [96, 101, 102]. Moreover, it was shown
that phosphorylation of Thr370 and Ser375 induced by DAMGO is
mediated by GRK2 whereas phosphorylation of Ser375 induced by
morphine is mainly put into effect by GRK5 [103].
gpcr signaling Binding of a ligand to a GPCR leads to activa-
tion of the receptor and, subsequently, the activation of a G protein
within a sub-second timeframe [61]. The activated receptor will then
recruit a GRK, which in turn phosphorylates one or more serine or
threonine residues at the C terminus of the receptor. The catalytic ac-
tivity of the GRK is activated by binding to the receptor [104]. Recent
findings suggest that different GRKs phosphorylate distinct serine or
threonine residues at the C terminus of a receptor and that this phos-
phorylation pattern influences the way β-arr promotes signaling into
the cell via specific conformational changes [105]. Furthermore, the
location and number of residues being phosphorylated was found to
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be ligand-dependent in at the µ receptor [106]; this, of course, adds a
whole new dimension to the complexity of receptor signaling. Phos-
phorylation of the receptor results in a high affinity for a β-arr, which
will be recruited to the receptor in a next step. Binding of β-arr to
the receptor terminates signaling and causes the G protein to dissoci-
ate from the receptor. By then, the G protein will have initiated two
distinct downstream signals: (1) activation/inhibition of an adenylyl
cyclase or activation of phospholipase C by the α subunit, depending
on the G protein subtype; (2) regulation of ion channels by the βγ
subunit complex.
The receptor-bound β-arr engages in G protein-independent sig-
naling pathways as has been described above. Still, it will first and
foremost facilitate the internalization of the receptor into endosomes
via the formation of clathrin-coated pits. While it was long thought
that internalized receptors were inactive, for two Gs coupled GPCRs,
the thyrotropin receptor (TSHR) [107] and the parathyroid hormone
receptor (PTHR) [108], it has been shown that they continue signal-
ing via cAMP after internalization. As a result, the activation of a
receptor causes cAMP levels in a cell to change more than once over
the course of time [109, 110]. In any case the internalized receptor
will traffic through various stages of endosomal compartments and
eventually be recycled to the cell surface or subjected to lysosomal
degradation [83].
1.3 µ-opioid receptor
Opioid receptors are a family of G protein-coupled receptors. There is
ongoing debate in the scientific community on how many subtypes of
opioid receptors exist. The International Union of Basic and Clinical
Pharmacology (IUPHAR) currently recognizes the following:
• δ-opioid receptor
• κ-opioid receptor
• µ-opioid receptor (µ receptor)
• nociceptin receptor
The δ, κ, and µ receptor show ∼60% amino acid sequence identity in
humans, the nociceptin receptor a little less so [111].
The activation of each opioid receptor subtype leads to a variety of
physiological effects. In general, µ receptors activation causes strong
analgesia together with respiratory depression, reward, and constipa-
tion as the most relevant undesired effects. All these effects are dimin-
ished in µ receptor knock-out animals [112–114]. Additionally, out-
comes in µ receptor-deficient animals depend on which of the exons
was deleted [115]. This finding has so far not led to consequences in
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opioid-based pain therapy, yet. δ-opioid receptors convey analgesia as
well, however usually at comparably high ligand concentrations. One
reason for this finding might be that δ-opioid receptors have repeat-
edly been shown to be localized preferably inside cells rather than
at the membrane, which, of course, makes them less accessible for
their ligands [116, 117]. However, the δ-opioid receptor seems to play
a role in morphine tolerance, a phenomenon which is diminished
in mice lacking the receptor [118]. Moreover, such receptor-deficient
mice show decreased levels of anxiety in behavioral studies [119]. An-
imals lacking of κ-opioid receptors have no altered overall nociceptive
sensitivity, however they are more sensitive to chemical visceral pain
and κ-selective agonists do not induce dysphoria in these animals as
would be expected in wild-type conspecifics [120].
The natural (endogenous) ligands of opioid receptors are peptides.
They share a common N-terminal sequence (Tyr-Gly-Gly-Phe-Leu or
Tyr-Gly-Gly-Phe-Met) [121]. In addition to that, many synthetic pep-
tide ligands are known. One such µ-sepecific peptide is DAMGO [29],
see section 1.1.
The µ-opioid receptor is the one among the opioid receptors, by
which the majority of the pharmaceutical drug effects are mediated.
All opioids in clinical use today are µ receptor ligands, but not all are
µ receptor-specific, e.g. buprenorphine (also see section 1.1). As a re-
ceptor in a contemporary sense it was first described in 1973 [122, 123]
and has been subject of extensive research ever since. The receptor
was eventually cloned in 1993 [124]. µ receptors are predominantly
expressed in the central nervous system, with enhanced expression
in the amygdala, the periaqueductal grey, the nucleus raphe magnus,
and the locus coeruleus (brain), as well as the dorsal horn (spinal
cord) [125]. Expression in the mesenteric plexus accounts for gastroin-
testinal side effects of opioids [126, 127]. Recent studies also suggest
a role of peripheral µ receptors [128]. The analgesic effect is mediated
by a hyperpolarization of afferent neurons by means of decreased
cAMP levels and increased intracellular potassium as a consequence
of inhibitory G protein activation (see section 1.2).
As with all opioid receptors, only one encoding gene is known for
each receptor, OPRM1 in the case of the µ receptor. However, to this
day ten splice variants have been identified [129] with uncertain phys-
iological relevance. Interestingly, there are subtype-specific ligands
(µ2 [130]); µ3 responds to alkaloid opioids but not peptides [131].
In this work the full-length human receptor as encoded by OPRM1
cDNA was used for all experiments.
An important contribution to the understanding of µ receptor func-
tion was made in 2012 when the crystal structure of an antagonist-
bound receptor was solved [58]. Two findings stood out: (1) the or-
thosteric binding pocket is very well accessible from the extracellular
space, notably more so than in many other GPCRs, where the lig-
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and is often partially buried by residues of the receptor’s TMs. This
allows for uncommonly bulky moieties to be attached to an agonist
scaffold without generally hindering proper binding. (2) The receptor
crystalizes as a dimer with two different interaction interfaces. This
is of interest, because oligomerization of (opioid) receptors has been
suggested before [132] and is subject to ongoing debate. Very recently,
the µ receptor crystal structure was solved with an agonist and a G
protein mimetic nanobody bound to it [133]. Furthermore, nuclear
magnetic resonance (NMR) studies confirmed the absolute need of a
G protein (or a structure mimicking its function) in order to obtain
the fully activated receptor state [134].
1.4 resonance energy transfer and its implications in
life sciences
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Figure 3: (a) Exemplary spectral properties of two compatible fluorophores.
The donor emission and the accpetor excitation spectra behave in
such a way that they overlap to some extent. This spectral over-
lap (light blue area) is required for RET of any kind to occur. (b)
Energy diagram of FRET. The acceptor gets excited (blue dashed
arrow). Instead of returning to a stable energy state by emitting
a photon (semi-transparent blue arrow), energy is transferred in
a radiation-free manner to the acceptor. Thus, the acceptor is in
an excited state and emits a photon of distinct wavelength (red
arrow). Adapted from [135]
fundamental principles of fret FRET is a physical concept
that describes radiation-free transfer of energy between two electric
dipoles over very short distances (several nanometers). The concept is
based on and named after work by German scientist Theodor Förster
[136]. Generally, FRET occurs between two apt molecules (the donor
and the acceptor) if they fulfill the following three conditions: (1)
donor and acceptor must be in close proximity, usually no more than
10 nm. (2) The optical spectra of donor and acceptor must behave in
such a way that the emission spectrum of the donor overlaps the exci-
tation spectrum of the acceptor to a certain degree (see figure 3a). (3)
For optimal energy transfer efficiency, the dipoles should be oriented
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in parallel to each other. In biochemical applications, compliance with
this last criterion is often times left to chance.
The eventual read-out in most FRET experiments is quantum yield,
i.e. the efficiency with which the donor transfers its energy to the
acceptor. This efficiency is dependent on the aforementioned three
criteria. Of particular importance is the distance between the two
chromophores, as the energy transfer efficiency is inversely propor-
tional to the sixth power of the distance. The radiation-free nature
of the energy transfer is often times deemed elusive, as its quantum-
mechanistic explanation involves the existence of a so called "virtual
photon" which facilitates the energy transfer. However, work by An-
drews [137] in 1989 pointed out that radiation-free and radiative en-
ergy transfer are merely the short-range and the long-range limit of a
common dipole-dipole interaction principle. At larger separations of
the two dipoles, relativistic effects will cause the transition from the
10−6 correlation between distance and efficiency of the radiation-free
transfer to the (more commonly known) 10−2 correlation for radiative
transfer [137, 138]. A graphic summary of the underlying proceedings
during FRET is given in the energy diagram in figure 3b.
fret applications First practical implementations of the Förster
principle were described in the 1960s and 1970s, when it was mainly
used as a spectroscopic ruler [139]. With present day microscopy tech-
nology at hand, FRET can be used to study interactions of molecules
in living cells in real time. An early approach to such an implementa-
tion was described by Uster and Pagano [140] in 1986. They used fluo-
rescence microscopy to measure FRET between fluorescent probes in
membranes of living cells. Today, three FRET applications for biomed-
ical research predominate [141]: (1) Photobleaching FRET, where con-
stant excitation of the donor causes the gradual loss of fluorescence,
a phenomenon called "photobleaching". The presence of a near-by
acceptor decreases the amount of photobleaching per time. The com-
parison of photobleaching rates with and without the acceptor yields
the FRET efficiency. (2) Fluorescence lifetime measurements make use
of the fact that an excited donor will take less time in that state before
emitting a photon when an acceptor is present. (3) In sensitized emis-
sion experiments, the FRET donor is excited by a light source and will
in turn excite the acceptor, if it is in close enough proximity. When
donor and acceptor change their distance from or relative orientation
towards each other due to movements of the molecules they are at-
tached to, a change in FRET efficiency can be observed. Sensitized
emission is the FRET technique used in this work. Technical details
are described in section 2.2.6.
fluorescent dyes As in this work, often times variants of green
fluorescent protein (GFP) are used as donor and acceptor, respectively.
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Figure 4: Cartoon rendering of a 1.9 Å crystal structure of the green fluo-
rescent protein of Aequorea victoria [142]. The barrel-like tertiary
structure is conserved in all GFP mutants. Image rendered from
PDB ID 1EMA using PyMol.
Many, yet not all of these fluorescent proteins are mutants of a fluores-
cent protein naturally expressed in the jellyfish Aequorea victoria (see
figure 4). It was found and described as a research tool in the 1990s by
several groups nearly at the same time [142–144]. Osamu Shimomura,
Martin Chalfie, and Roger Y. Tsien were awarded the Nobel Prize in
Chemistry in 2008 for "the discovery and development of the green
fluorescent protein, GFP".1 Today, a wealth of GFP variants, other
fluorescent proteins, and fluorescent small molecules can be used as
FRET interaction partners [145]. The decision for a specific pair of
fluorophores will eventually be influenced by practical biotechnical
considerations besides the pure physical requirements that need to be
met. For example, fluorescent proteins can be fused to the protein of
interest genetically, i.e. both are expressed as one fusion protein. This
can be an advantage as no labeling is required. However, the relatively
large size of GFP (27 kDa) can interfere with the biological processes
that were to be investigated in the first place. Small molecules can be
an alternative in this case. Yet, these are of non-peptide nature, which
means they need to be attached to the protein of interest in a separate
process. This usually requires a specific binding site to be introduced
into the protein, which then can bind the fluorophore. Depending on
the technique used, such binding sites can themselves be several kDa
to only six amino acids in size [146, 147].
bret A more recent variation of FRET which has been established
in biomedical research is BRET. There, instead of a donor fluorophore,
a light-emitting enzyme - a so-called luciferase - is genetically fused
to one of the interaction partners [148]. One major advantage is the
loss of an external light source, which tends to significantly add to the
noise in FRET experiments. Additionally and for several reasons not
1 "The Nobel Prize in Chemistry 2008 - Press Release". Nobelprize.org.
Nobel Media AB 2014. Retrieved from the internet 17 Jan 2016.
<http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2008/press.html>
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Figure 5: Principle of FRET and BRET in protein interaction sensors used in
this work. Note that the FRET sensor (A) requires an external light
source for the excitation of the donor fluorophore. Donor and ac-
ceptor are fused to a subunit of a trimeric G protein, respectively.
Activation of the G protein by an agonist-bound receptor will lead
to movement of the subunits relative to each other, thereby chang-
ing the fluorophores’ distance from and/or orientation towards
each other. The donor in BRET (B) is a luciferase fused to the re-
ceptor, which emits light of a distinct wavelength spectrum in the
presence of its substrate. When the β-arr, which is fused to the
acceptor fluorophore, binds to the activated receptor, the two flu-
orophores will be in close enough proximity for resonance energy
transfer to occur. In both applications, donor and acceptor emis-
sions are recorded separately and the ratio of both serves as a
quantitative readout.
to be outlined in detail, BRET is superior to FRET in high-throughput
screening [149]. Together, FRET- and BRET-based biosensors have
proven to be valuable tools for a diversity of applications: protein-
protein interactions [150], detection of intramolecular conformational
changes [61], and real-time determination of cytosolic second messen-
ger concentrations [151], just to name a few. A simplified depiction
of exemplary FRET and BRET sensors used in this work is given in
figure 5.
1.5 biased agonism
priniciples of biased agonism The concept of biased agonism
(sometimes also termed functional selctivity) was introduced to the
scientific community at the beginning of this century. In brief, biased
agonism describes the propensity of a (G protein-coupled) receptor
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to transduce different downstream signaling patterns to the cytosol
depending on the ligand it was activated by. To put it another way,
two ligands, both agonists at the same receptor, can elicit different
downstream signaling. Until recently, when a receptor was thought
of as a machine which can exist in exactly two distinct states - on and
off - it has been hard to conceive how this one active receptor state
would be capable of modulating fine-tuned signaling patterns.
In terms of GPCR biased agonism, one straightforward example
is selectivity of a ligand for either G protein activation or β-arr re-
cruitment. While most ligands tend to engage in both signaling path-
ways, they do so to different extents. It was shown that at the β2-AR,
carvedilol is a β-arr-biased agonist [152]. Moreover, it induced phos-
phorylation of the receptor at sites which were found to be phos-
phorylated only by GRK6 but not GRK2 [105]. This idea of a "phos-
phorylation barcode" was also propagated for the µ receptor [153],
where different phosphorylation patterns lead to distinct signaling
outcomes [99, 154]. Apart from β-arr-related signaling, it was also
shown that a biased ligand can selectively target signaling through
single G protein subunits [155].
As mentioned above, receptors were imagined to appear in one
on and one off-state until only several years ago. With the develop-
ment of ever more sophisticated technical possibilities, this concept
is facing growing challenge. For example, by means of fluorescence
spectroscopy, Swaminath et al. [156] could show multiple active states
of the β2-AR. Similarly, Liu et al. [157] found conformational states
for G protein and β-arr-biased ligands. Using NMR techniques, they
showed that G protein-specific active states are effected through con-
formational changes in transmembrane helix VI and ICL3, whereas
bias towards β-arr is effected through the conformation of helix VII
(for orientation, see figure 1). Changing the equilibrium of confor-
mational changes in those two regions is suggested to be the mech-
anistic correlate of biased agonism at the β2-AR and could serve as
a general model to explain this phenomenon at GPCRs. The latest
model of GPCR activation depicts the receptor as a highly dynamic
entity which spontaneously and rapidly switches between several un-
stable conformations. The mechanistic basis of this is a complex so-
called "energy landscape" that is influenced by bound ligands and ef-
fector molecules likewise. Different constellations of receptor-ligand-
effector interactions stabilize distinct energy profiles resulting in re-
ceptor conformations and thereby also explaining biased agonism
[158, 159].
quantification of biased agonism With these conceptual
considerations in mind, the need for experimental quantification of bi-
ased agonism arises. Several approaches have been suggested to this
day. One way or another, they all compare efficacies and/or poten-
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cies of ligands across a given set of signaling pathways. The simplest
way of comparing ligand signaling efficiencies would be to compare
(1) signal amplitudes at a given ligand concentration (equimolar ap-
proach) or (2) ligand concentrations required to elicit the same signal
(eqiactive approach). Both have been described in the literature [160–
162]. Both approaches often make use of output parameters from stan-
dard three- or four-parameter sigmoidal fits, i.e. maximum response
(Emax) and concentration of half-maximum response (EC50). The main
concern with these two approaches is that they are not very robust
with respect to confounding influences. Specifically, these approaches
do not take into consideration the receptor density, the coupling effi-
ciency with signal transducers (e.g. G proteins), and amplification of
downstream signals (e.g. cAMP levels). In addition, signaling prop-
erties of a ligand can differ tremendously between single-cell and in
vivo experiments [163]. Thus, the detection of weak bias is difficult
and one can merely describe qualitative bias. Therefore, more elabo-
rate ways for bias quantification were developed. Such truly quantita-
tive approaches in a way combine the aforementioned methods and
expand them by using an operational model of receptor pharmacol-
ogy (Black and Leff [164]). Two slightly different ways of bias calcula-
tion predominate in the scientific community to this date: Rajagopal
et al. [165] and Kenakin et al. [166]. The two approaches mainly dif-
fer in the necessity of expressly gathering binding data for the ligands
under investigation. While Rajagopal et al. support independent bind-
ing experiments, Kenakin et al. state that ligand affinity is dependent
on the transducer bound to the receptor at any given time. There-
fore, mere binding affinities might not be of great use and they claim
the term KA of the operational model represents "functional affinity"
and is, as such, integrated in the pharmacological model in the first
place. Either way, no clear evidence for the superiority of one of the
approaches was shown and it seems like they yield rather similar re-
sults [165]. As of now, there is ongoing debate between the leading
authors (Kenakin and Christopoulos [167] and Rajagopal [168]), but
powerful tools for the quantification of ligand bias do exist. In this
work, the approach by Kenakin et al. was chosen, not least because of
their convincing points about ligand binding experiments. Technical
details of the calculations are given in section 2.2.11. For a compre-
hensive review on the matter of biased agonism, see [169].
clinical implications In recent years, pharmaceutical research
has started to take advantage of the insights into biased agonism. In
conditions where one signaling pathway of a given receptor is known
to have beneficial effects, while another might be less favorable, tar-
geted screening for biased ligands can be a promising approach. For
example, a β-arr-biased angiotensin II receptor type 1A (AT1A-R) lig-
and was shown to have positive inotropic and lusitropic effects in
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cardiac myocytes in vitro [170]. With TRV027, such a β-arr-biased
AT1A-R agonists has proven to have beneficial effects on acute heart
failure in vivo, too [171] and is currently in phase-II clinical testing
[172]. Another biased ligand, TRV130, is a µ receptor agonist biased
for Gi protein activation. After experiments with β-arr2 knock-out
mice showed enhanced analgesia and reduced desensitization upon
morphine treatment [173], also severe side effects of morphine like
respiratory depression and obstipation were found to be attenuated
in such animals [174]. The thereafter identified compound TRV130
showed favorable behavior in vitro and in vivo [175] and was granted
Breakthrough Therapy status by the U.S. Food and Drug Administra-
tion (FDA) in early 2016 (Oliceridine, OLINVOTM) for the therapy of
moderate to severe pain.
1.6 toll-like receptor 4 and its involvement in opioid
signaling
Toll-like receptors are a family of mammalian pattern recognition recep-
tors. They play an important role in the innate immune system, as
they detect structures possibly harmful to the organism - so called
pathogen-associated molecular patterns (PAMPs) - without previous
sensitization. Unlike GPCRs, TLRs span the plasma membrane only
once (see figure 6). Their name is derived from homology to the toll
gene in Drosophila.
tlr4 general remarks The human TLR4 was the first toll-ana-
logous structure identified in humans [176]. To this day, thirteen TLRs
are known, ten of which are expressed in humans. TLR4 responds to
several PAMPs. The one most looked into so far probably is lipopoly-
saccharide (LPS), which is part of the cell wall of gram-negative bac-
teria [177]. For their ground-breaking work on innate immunity and
TLRs in particular, Bruce A. Beutler and Jules A. Hoffmann were
awarded one half of the Nobel Prize in Medicine or Physiology in
2011.2
TLR4 does not confer signaling by itself, but interacts with other
proteins [178, 179]. CD14 is expressed on the surface of lymphatic
cells and is the genuine, high-affinity LPS binding protein. It has no
signaling capacity of its own but merely binds LPS and mediates
binding to TLR4. Furthermore, MD-2, a soluble protein, also binds
the LPS-TLR4-CD14 complex. TLR4 signaling is abolished with no
MD-2 present [178]. For intracellular signal transduction there are
two major pathways. One is common to several TLRs and is effected
by a protein called MyD88. MyD88 is an adaptor protein which then
2 "The 2011 Nobel Prize in Physiology or Medicine - Press Release". Nobelprize.org.
Nobel Media AB 2014. Web. 23 Jan 2016.
<http://www.nobelprize.org/nobel_prizes/medicine/laureates/2011/press.html>
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Figure 6: Cartoon rendering of a 2.4 Å crystal structure of a TLR4 dimer
(blues) in complex with MD-2 (green). Rendered using PyMol
from PDB ID 4G8A.
recruits a cascade of effectors, finally resulting in the release of NF-
κB and inflammatory cytokines [180]. The other signaling pathway is
specific to TLR4 and originates from an adaptor protein called TIRAP
or Mal. TIRAP-dependent signaling will lead to the production of
Interferon type I. Moreover and similar to the MyD88 pathway, it will
also induce a (late) NF-κB release [180, 181]. An abriged scheme of
signaling processes at the TLR4 is given in figure 7. The immunologic
significance of TLR4 is stressed further by the identification of single
nucleotide polymorphisms in humans. Most profoundly investigated
so far are the two polymorphisms D229G and T399I. They seem to be
related to an increased susceptibility to gram-negative infections and
septic shock [182–184].
tlr4 and opiods The involvement of TLR4 in pain and opioids
is not all obvious and has been postulated only in the last ten years. In
2005, Tanga et al. [185] reported a role of TLR4 as a glial activator in
the central nervous system that could induce neuropathy. Based upon
these findings, Hutchinson et al. [186] postulated both stereoisomers
of Naltrexon to be antagonists of TLR4. As such, they would be able
to alleviate neuropathic pain. Two years later, the morphine metabo-
lite morphine-3-glucuronide was found to induce allodynia and hy-
peralgesia (both painful conditions) in rats. This effect was ascribed
to TLR4s expressed in spinal cord microglial cells [187]. This work
also suggested possible morphine binding to MD-2 in a way similar
to LPS in in silico docking studies. This hypothesis was confirmed
biochemically by Wang et al. [188], who further postulated morphine
was able to induce TLR4 dimerization, which is a generally accepted
part of the receptor activation cascade. A central work on opioid
effects on TLR4 signaling was published in 2010. Herein, the au-
thors found several opioid agonists to activate TLR4 signaling in the
same in vitro assay used in this work [189]. Those were, among oth-
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CD14 MD-2
MyD88
NF-κB interferon I
TRIF
Figure 7: Basic schematic of TLR4 signaling. For reasons of simplicity, not
all signaling and adaptor proteins involved are depicted.
ers, (+)- and (-)-morphine, (+)- and (-)-methadone, oxycodon, pethi-
dine, buprenorphine, fentanyl, and morphine-3-glucuronide. Interest-
ingly, M-6-G was no TLR4 agonist in this study. Both stereoisomers of
Naloxone inhibited opioid induced TLR4 signaling in a concentration-
dependent fashion. Moreover, the authors found blocking of TLR4 to
support morphine induced analgesia and attenuate tolerance, hyper-
algesia, and withdrawal symptoms in rats. In TLR4 knock-out ani-
mals morphine analgesia was found to be more potent than in the
wild-type. In 2013, work by a different group showed results not
entirely in line with the previous findings. Morphine and fentanyl
were found to produce close to no signal in a comparable in vitro
assay, whereas they acted as non-competitive antagonists when ad-
ministered together with LPS [190].
In summary, the significance of opioid signaling at the TLR4 is far
from clear to this day. Especially so, as parts of the work by Hutchin-
son in 2010 could not be reproduced by another lab a few years later
[191]. However, some of the findings are intriguing and more efforts
will need to be made to resolve the issue.
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1.7 aim of this work
Probably unlike any other class of drugs, when it comes to opioids,
"clinical" utilization has preceded basic research for the major part
of their existence. As a result, many opioid drugs are in use today
with comparatively little knowledge available about the molecular
processes which are influenced by them. Yet, opioids remain the gold
standard in the therapy of severe pain despite a variety of substan-
tial undesired effects with no alternatives is the foreseeable future.
With this in mind, a more detailed understanding of the signaling
processes surrounding opioid therapy is urgently needed. From the
existence of endogenous opioids and the observations on how they
work, one must assume that much more effective and at the same
time safer therapeutic opioids should be possible. To achieve this
goal, several mechanisms need to be uncovered, especially the exact
signaling properties on a molecular level of each opioid in use today.
This also includes pathways that go beyond what is now considered
to confer analgesia. Recent findings show that a lot more signaling
is activated by opioid drugs than would be necessary for pain re-
lieve alone. With the latest insights into biased agonism, a first step
into designing more advanced analgesics is to identify ways to under-
stand and make use of biased signaling in such a way that it allows
for more "analgesia-specific" opioids. This work seeks to contribute
to that by (1) describing signaling efficiencies for a wide range of
clinically used opioids in a systematic approach. The focus lies on
G protein activation and recruitment of β-arr 1 and 2. (2) Applying
recent insights into biased agonism on the opioid system in order to
identify possibly biased ligands among those already in use. Efforts
of the pharmaceutical industry highlight the potential of such sub-
stances. Having a biased ligand approved for use in patients would
allow for far reaching clinical research on the matter of biased ago-
nism, thus connecting molecular and applied research. (3) Exploring
the possibility that structures and systems beyond the classic opioid
system are involved in the way these drugs exert their influence in
an organism. Recent studies suggested TLR4 as a potential receptor
engaged in opioid signaling. As a start, this work aims to reproduce
previous experiments with opioid ligands in a TLR4 signaling assay
to lay the groundwork for possible future research extending beyond
this very piece of work.
2
M AT E R I A L S A N D M E T H O D S
2.1 materials
2.1.1 Chemicals and Reagents
Agar Applichem, Darmstadt, Germany
Ampicillin-Na Sigma-Aldrich, Taufkirchen, Germany
Benzamidine-HCl 99% Sigma-Aldrich, Taufkirchen, Germany
Bovine serum albumin (BSA) New England Biolabs, Frankfurt/Main,
Germany
Calcium chloride (CaCl2) Applichem, Darmstadt, Germany
Dimethyl sulfoxide (DMSO) BioChemica/Applichem, Darmstadt, Germany
Ethidium bromide Applichem, Darmstadt, Germany
Ethanol Roth, Karlsruhe, Germany
G418 (Geneticin sulphate) Gibco Life Technologies Eggenstein, Germany
Glucose, anhydrous Applichem, Darmstadt, Germany
HEK-Blue TM Detection InvivoGen, San Diego, CA, USA
HEK-BlueTM Selection InvivoGen, San Diego, CA, USA
HEPES Applichem, Darmstadt, Germany
Immersion oil for microscopy Applichem, Darmstadt, Germany
Isopropanol Sigma-Aldrich, Taufkirchen, Germany
KCl Applichem, Darmstadt, Germany
L-glutamine 200 mM Sigma-Aldrich, Taufkirchen, Germany
Lipopolysaccharide (LPS) InvivoGen, San Diego, CA, USA
Methanol Sigma-Aldrich, Taufkirchen, Germany
MgCl2∗6H2O Applichem, Darmstadt, Germany
Milk powder Applichem, Darmstadt, Germany
NaCl Applichem, Darmstadt, Germany
NaOH Applichem, Darmstadt, Germany
Nonidet P40 Sigma-Aldrich, Taufkirchen, Germany
Normocin
TM
InvivoGen, San Diego, CA, USA
Penicillin G 10000 U/ml, Sigma-Aldrich, Taufkirchen, Germany
Streptomycin sulfate 10 mg/ml
PMSF ThermoFisher Scientific, Brunswick, Germany
Poly-D-Lysine hydrobromate MP Biomedicals, Eschwege, Germany
PEG 3000 Applichem, Darmstadt, Germany
SDS Sodium dodecyl sulfate Applichem, Darmstadt, Germany
Soybean trypsin inhibitor Sigma-Aldrich, Taufkirchen, Germany
TEMED Sigma-Aldrich, Taufkirchen, Germany
Tris-acetate Applichem, Darmstadt, Germany
Tris∗HCl Applichem, Darmstadt, Germany
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Tryptone Applichem, Darmstadt, Germany
Tween 20 Applichem, Darmstadt, Germany
Universal agarose Peqlab, Erlangen, Germany
Yeast-extract Applichem, Darmstadt, Germany
Zeocin (phleomycin D1) InvivoGen, San Diego, CA, USA
2.1.2 Cell Culture Consumables
dmem+++
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
to contain 2mM L-glutamine, 0.1 U/l penicillin G, 0.1 g/l strep-
tomycin sulfate, and 10% fetal calf serum (FCS)
dmem+++ (stable cells)
DMEM+++ containing 40mg/l Zeocin and 800 mg/l G418, ad-
ditionally
dmem cell freezing medium
Dulbecco’s modified eagle medium supplemented to contain
4.5 g/l glucose containing 2 mM L-glutamine, 0.1 U/l penicillin
G, 0.1 g/l streptomycin sulfate, 10 % FCS and 10 % dimethyl
sulfoxide (DMSO)
dpbs
Dulbecco’s phosphate buffered saline (Sigma-Aldrich,
Taufkirchen, Germany)
effectene R© transfection reagent
for transfection of eukaryotic cells (Qiagen, Hilden, Germany)
kcm buffer 5x
500 mM potassium chloride (KCl), 150 mM calcium chloride
(CaCl2), 250 mM magnesium chloride (MgCl2); for transforma-
tion of competent E. coli
lysogeny broth (lb)
16g/l peptone, 10 g/l yeast, 5 g/l sodium chloride (NaCl)
lb with selective antibiotics
80 µg/l ampicillin or 50 µg/l kanamycin, respectively
lb agar
LB supplemented to contain 8 g/l agar
opti-mem R©
Modified Eagle’s minimum essential media, no phenol red (Ther-
moFisher Scientific, Waltham, MA, USA)
trypsine-edta solution
(PAN-Biotech Aidenbach, Germany)
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2.1.3 Molecular Biology
PCR DNA primers were custom-synthesized by Eurofins Genomics,
Ebersberg, Germany. Thermus aquaticus (Taq) deoxyribonucleic acid
(DNA) polymerase, restriction enzymes, bacteriophage T4 (T4) DNA
ligase and their corresponding buffers were from New England Bio-
labs, Frankfurt, Germany. Purification of polymerase chain reaction
(PCR) products from agarose gels (1% agarose in Tris base, acetic
acid, EDTA (TAE) buffer) was done with a DNA gel extraction kit
(Merck Millipore, Darmstadt, Germany). DNA preparation from E.
coli lysates was performed using the NucleoBond R© Xtra Midi kit
(Macherey Nagel, Düren, Germany).
Cloning Vectors
pcdna3 vector
Invitrogen, Darmstadt, Germany
pcdna3 .1 vector
Invitrogen, Darmstadt, Germany
pfc14k halotag R© cmv flexi R© vector
Promega, Mannheim, Germany
pfc15k halotag R© cmvd1 flexi R© vector
Promega, Mannheim, Germany
pfc16k halotag R© cmvd2 flexi R© vector
Promega, Mannheim, Germany
pfc17k halotag R© cmvd3 flexi R© vector
Promega, Mannheim, Germany
pfn21k halotag R© cmv flexi R© vector
Promega, Mannheim, Germany
pfn22k halotag R© cmvd1 flexi R© vector
Promega, Mannheim, Germany
pfn23k halotag R© cmvd2 flexi R© vector
Promega, Mannheim, Germany
pfn24k halotag R© cmvd3 flexi R© vector
Promega, Mannheim, Germany
pfc32k nluc cmv-neo flexi R© vector
Promega, Mannheim, Germany
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cDNA
oprm1
human µ receptor, transcript variant 1 (provided by C. Hoff-
mann)
arrb2
bovine β-arr2 (provided by C. Hoffmann)
Plasmids
µ receptor (oprm1) in pcdna3
provided by C. Hoffmann
gβ -2a-venus-gγ2 -ires-gα i1 -mtq2 in pegfp-c1
provided by J. Goedhart
grk2 in pcdna3
provided by C. Hoffmann
pfc32k-oprm-nluc in cmv-neo flexi R© vector
this work; U. Zabel
pfc14k-β-arrestin2-halotag in cmv flexi R© vector
this work; U. Zabel
pfc15k-β-arrestin2-halotag in cmvd1 flexi R© vector
this work; U. Zabel
pfc16k-β-arrestin2-halotag in cmvd2 flexi R© vector
this work; U. Zabel
pfc17k-β-arrestin2-halotag in cmvd3 flexi R© vector
this work; U. Zabel
pfn21k-halotag-β-arrestin2 in cmv flexi R© vector
this work; U. Zabel
pfn22k-halotag-β-arrestin2 in cmvd1 flexi R© vector
this work; U. Zabel
pfn23k-halotag-β-arrestin2 in cmvd2 flexi R© vector
this work; U. Zabel
pfn24k-halotag-β-arrestin2 in cmvd3 flexi R© vector
this work; U. Zabel
2.1.4 Western Blot
The following buffers and solutions were prepared:
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aps 10% ammonium persulfate in water (H2O)
laemmli sample buffer
50 ml Tris(hydroxymethyl)aminomethane (Tris) 1M pH 6.8, 50
ml sodium dodecyl sulfate (SDS) 20%, 100 ml Glycerol 20%, 0.01
g bromophenol blue, ad 200 ml H2O
upper buffer
2 g SDS, 250 ml Tris 1M pH 6.8, ad 500 ml H2O
lower buffer
4 g SDS, 500 ml Tris 3M pH 8.8, ad 1000 ml H2O
running buffer 10x
30.3 g Tris, 144 g Glycine, 10 g SDS, ad 1000ml H2O
transfer buffer
2.4 g Tris, 11.2 g Glycine, 200 ml Methanol, ad 1000 ml H2O
phosphatase inhibitor
50 mM sodium pyrophosphate (Na4P7O2), 1mM sodium ortho-
vanadate (Na3VO4), 0.02% sodium azide (NaN3), in H2O
protease inhibitor
2 mg/ml soybean trypsin inhibitor, 6 mg/ml benzamidine, in
50 mM Tris
pmsf
100mM phenylmethylsulfonyl fluoride (PMSF) in ethanol
blocking buffer
15 g milk powder, 1.75 g NaCl, 3 ml Tris 1M pH 7.6, 0.3 ml
Tween 20
wash buffer
50 ml Tris 1M pH 7.4, 8.8 g NaCl, 2 g bovine serum albumin
(BSA), 2 ml Nonidet P-40 2 ml, ad 1000 ml H2O
towbin buffer
3.03 g Tris base, 14.4 g glycine, 500 ml diH2O, 200 ml methanol,
ad 1000 ml diH2O
The following antibodies were used for protein detection:
anti-halotag mouse monoclonal antibody g9211
Promega, Mannheim, Germany
anti-grk2 c15 rabbit antibody sc-562
Santa Cruz Biotechnologies, Heidelberg, Germany
anti-β-actin mouse antibody a5441
Sigma-Aldrich, Taufkirchen, Germany
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Protein quantification was done using the PierceTM BCA protein assay
kit (ThermoFisher Scientific, Brunswick, Germany).
Antibodies were used in the concentrations and with buffers recom-
mended by the respective manufacturer.
Electrophoresis was performed in a Mini-PROTEAN R© Tetra Verti-
cal Electrophoresis Cell (Bio-Rad Laboratories, Munich, Germany).
Proteins were blotted onto Immobilon-P membranes (Merck Chem-
icals, Darmstadt, Germany) membranes using a Trans-Blot R© Semi-
Dry Transfer Cell (Bio-Rad Laboratories, Munich, Germany).
Amersham ECL Western Blotting Detection Reagent (GE Healthcare,
Freiburg, Germany) was used for chemiluminescent detection on an
ImageQuant LAS4000 biomolecular imager (GE Healthcare, Freiburg,
Germany).
2.1.5 Cell Lines
All living cell experiments were performed in human embryonic kid-
ney (HEK)-293 cells. Competent E. coli were used for plasmid trans-
formation.
hek-293 cells were provided by Prof. Hoffmann.
hek elucc-oprm1/arrb1-elucn and
hek elucc-oprm1/arrb2-elucn
stably transfected cells were generously provided by Prof. Ozawa
(Tokyo, Japan).
hek-blue
TM
htlr4 cells
were purchased from InvivoGen, San Diego, CA, USA
hek-blue
TM
null2 cells
were purchased from InvivoGen, San Diego, CA, USA
competent e . coli dh5αTM
were purchased from Invitrogen, Darmstadt, Germany.
2.1.6 Opioids
buprenorphine hydrochloride
Reckitt Benckiser Healthcare, Slough, UK
[d-ala2 , n-me-phe4 , gly-ol]-enkephalin
Bachem, Weil am Rhein, Germany
fentanyl citrate
Braun Melsungen, Melsungen, Germany
hydromorphone hydrochloride
Sigma-Aldrich, Taufkirchen, Germany
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levomethadone hydrochloride
Sanofi-Aventis Deutschland, Frankfurt, Germany
morphine hydrohcloride
Caesar & Loretz, Hilden, Germany
morphine-6-glucuronide
Sigma-Aldrich, Taufkirchen, Germany
naloxone hydrochloride
Braun Melsungen, Melsungen, Germany
naltrexone hydrochloride
Sigma-Aldrich, Taufkirchen, Germany
oxycodon hydrochloride
Mundipharma, Limburg, Germany
pethidine hydrochloride
Hameln Pharmaceuticals, Hameln, Germany
piritramide
Janssen-Cilag, Neuss, Germany
remifentanil hydrochloride
GlaxoSmithKline, Munich, Germany
sufentanil hydrogen citrate
Janssen-Cilag, Neuss, Germany
tapentadol hydrochloride
Sigma-Aldrich, Taufkirchen, Germany
tilidine
Gödecke, Germany (now Pfizer)
tramadol hydrochloride
Grünenthal, Aachen, Germany
2.1.7 Custom-made Buffers and Solutions
fret measuring buffer
140 mM NaCl, 5.4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH
7.3
kcm buffer 5x
500 mM KCl, 150 mM CaCl2, 250 mM MgCl2
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2.1.8 Microscopes and Other Instruments
axiovert 200 inverted microscope
Zeiss, Jena, Germany
leica tcs sp8 confocal microscope
Leica, Wetzlar, Germany
envision 2104 microtiter plate reader
Perkin Elmer, Waltham, MA, USA
glomax discover microtiter plate reader
Promega, Mannheim, Germany
spectramax plus 384 spectrophotometer
Molecular Devices, Sunnyvale, CA, USA
thermomixer
Eppendorf, Hamburg, Germany
applied biosystems 2720 thermal cycler
Thermo Fisher, Brunswick, Germany
nanodrop spectrophotometer
Thermo-Fisher, Brunswick, Germany
2.1.9 Expendable Supplies and Materials
cell culture dishes and flasks
Nunc Fisher Scientific, Schwerte, Germany
cell scrapers
Hartenstein Laborbedarf GmbH, Würzburg, Germany
cryo-tubes
Nunc Fisher Scientific, Schwerte, Germany
falcon tubes
BD Biosciences, Heidelberg, Germany
glass coverslips 24 mm
Hartenstein Laborbedarf GmbH, Würzburg, Germany
multi-well plates
Nunc Fisher Scientific, Schwerte, Germany
Sarstedt, Nümbrecht, Germany
Brandt, Wertheim, Germany
pipet tips
Eppendorf, Hamburg, Germany
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2.1.10 Software
adobe creative suite 6 Adobe Systems, San Jose, CA, USA
axoscope 10 .3 Molecular Devices, Sunnyvale, CA, USA
clampex 10 .3 Molecular Devices, Sunnyvale, CA, USA
graphpad prism 6 GraphPad, La Jolla, CA, USA
fiji/imagej open-source freeware
leica las af Leica, Wetzlar, Germany
office for mac 15 .15 Microsoft, Redmond, WA, USA
origin 9 .1 Origin Labs, Northampton, MA, USA
snapgene viewer 2 .8 GSL Biotech, Chicago, IL, USA
2.2 methods
2.2.1 Eukaryotic Cell Culture
HEK-293 cells for transient transfection were kept in DMEM+++, sta-
ble HEK-293 cell lines were kept in the respective DMEM+++ sup-
plemented with suitable selective antibiotics. These were Zeocin and
G418 for the stable split-luciferase cell lines (HEK ElucC-OPRM1/
ARRB1-ElucN and HEK ElucC-OPRM1/ARRB2-ElucN), Normocin
and Zeocin for the HEK-Blue Null2 cells, and Normocin, Zeocin,
and HEK-Blue SelectionTM for the HEK-Blue hTLR4 cells, respectively.
Cells were cultured at 37 ◦C in a 5% carbon dioxide (CO2) atmosphere
and routinely split every two to three days at ∼60% confluency. Be-
fore splitting, HEK cells were washed gently with a few milliliters
of Dulbecco’s phosphate buffered saline (DPBS), which was imme-
diately removed afterwards. The cells were then treated with 1 ml
trypsin-ethylenediaminetetraacetic acid (EDTA) for 30 seconds. Su-
pernatant trypsin was removed. The cell culture dish was tapped vig-
orously several times until the cells detached from the bottom of the
dish. Subsequently, the cells were resuspended in 5 ml of DMEM+++,
thus deactivating the remainder of the trypsin and seeded to a new
culture dish (10 or 20 mm) in a sufficient volume of fresh growth
medium.
For FRET experiments on Gi activation, cells were harvested at
∼40% confluency, seeded to D-polylysine-coated 24 mm round glass
cover slips, and kept in 6-well plates. There they were kept in the
incubator overnight in order for the cells to adhere properly to the
glass. Then, the cells were transfected with 2.5 µg/plate human wild-
type µ-opioid receptor (OPRM) DNA and 2.5 µg/plate Gi trimer
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(Gαi-mTq2-Gβwt-Gγ-Venus) DNA using Effectene transfection reagent
according to the manufacturer’s protocol (20 µl enhancer, 50 µl Ef-
fectene). Growth medium was renewed after 24 hours and experi-
ments were performed after a total of 48 hours.
In the µ receptor:β-arr interaction luciferase complementation ex-
periments, HEK-293 cells were used which stably expressed the µ receptor
and β-arr 1 or 2 with half an enhanced click beetle luciferase (Eluc) ge-
netically attached to the receptor and the arrestin, respectively (HEK
ELucC-OPRM1 / ARRB1-ELucN and HEK ELucC-OPRM1 / ARRB2-
ELucN). The used constructs were designed by our collaborator in
analogy to previously published GPCR/β-arr split luciferase pairs
[192]. In preparation of the experiments, cells were harvested at 70%
confluency and seeded onto 96-well microtiter plates (72,000 cells/well).
The seeded cells were incubated in phenol red-free DMEM without
selective antibiotics at 37 ◦C in a 5% CO2 atmosphere for 24 hours.
For the µ receptor:β-arr2 BRET experiments, 1.0·106 HEK-293 cells
were seeded to a regular 55 mm cell culture dish. After 3 hours in the
incubator at 37 ◦C the cells were eventually transfected with 0.2 µg
OPRM-Nluc DNA, 2 µg β-arr2-HaloTag DNA, and, when indicated,
1 µg GRK2 DNA. Growth medium was renewed after 24 hours. 48
hours after transfection the cells were counted again and 18,000 cells
per well were seeded to a 96-well plate in Opti-MEM growth medium.
The seeded cells were given three hours to attach to the wells’ bottoms
before experiments were performed. Counting of cells was done in a
Neubauer counting chamber in each instance.
HEK-Blue TLR4 experiments were performed under the most asep-
tic conditions possible at all times. HEK-Blue hTLR4 were kept in
DMEM+++ additionally supplemented with 100 µg/ml Normocin
and 1x HEK-Blue Selection, which are both mixtures of (selective) an-
tibiotics undisclosed by the manufacturer. HEK-Blue Null2 cells were
cultured in DMEM+++ additionally supplemented with 100 µg/ml
Normocin and 100 µg/ml zeocin. Both cell lines were seeded to 75
ml cell culture flasks, kept in a 5% CO2 atmosphere at 37 ◦C in an
incubator for tested mycoplasma-free cells only, and split regularly
every two to three days as elaborated above.
Whenever it was necessary to freeze HEK cells for later use, they
were grown on 200 mm cell culture dishes to ∼80% confluency. After
gentle washing with DPBS they were detached as described before
and resuspended in 5 ml DMEM+++ freezing medium. 1 - 1.25 ml of
this suspension were transferred into each cryo tube and put into an
iced tube rack, immediately. The tubes were put in a -20 ◦C freezer
overnight, immediately. After that, the tubes were transferred either
to a -80 ◦C freezer or liquid nitrogen for long-term storage.
2.2 methods 33
2.2.2 E. coli Transformation
Competent E. coli (stored at -80 ◦C) were slowly thawed on ice. Af-
terwards, ∼50 ng of the desired plasmid DNA were mixed with 100
µl of E. coli suspension and 100 µl KCM buffer stock solution and
incubated for 20 minutes on ice and another ten minutes at room
temperature. Next, 900 µl lysogeny broth (LB) were added and the
suspension was incubated in a ThermomixerTM at 37 ◦C shaking at
300 rpm.
After incubating, the suspension was centrifuged at 200·g for 5 min-
utes. Most of the supernatant was discarded, the rest was used to re-
suspend the bacteria pellet. Of this suspension, 50-100 µl, depending
on prior transformation efficiency, were plated onto an LB agar dish
with the selective antibiotic (ampicillin or kanamycin) and kept at 37
◦C overnight.
On the following day, a single colony was picked and cultured
overnight in LB with selective antibiotics at 37 ◦C, shaking at 300
rpm.
2.2.3 DNA Midi Preparation
Preparation of plasmid DNA from E. coli transformed as described
above was performed using the NucleoBond Xtra kit (Macherey-Nagel,
Düren, Germany) according to the manufacturer’s instructions. DNA
concentration and purity were measured using a NanoDrop 2000
spectrophotometer. When needed, DNA was diluted in purified H2O.
Dissolved plasmid DNA was stored at -20 ◦C.
2.2.4 Cloning of µ Receptor / β-Arrestin2 BRET Constructs
The purchased NanoBRET R© expression vectors come in a variety
of versions. Both the NanoLuciferase (Nluc) and the HaloTag vec-
tors exist with the target protein DNA insertion site upstream or
downstream of the luciferase or HaloTag coding region, respectively.
This allows to determine the position of the desired protein rela-
tive to Nluc/HaloTag (C-or N-terminal). Additionally, the HaloTag
vectors come in four different versions for C- and N-terminal ex-
pression, each. Those four vector variants differ in the length of the
cytomegalovirus (CMV) promotor, which is supposed to control pro-
tein expression levels in a differentiated manner. That is why there is
one vector with the full CMV promotor (742 bases) and three more
with gradually truncated promotors (121, 73, and 66 bases; see fig-
ure 8). Findings of this work could confirm the usefulness of trun-
cated promotors only to a certain degree (see figure 13).
The plasmid constructs used in this work were cloned by Ulrike
Zabel roughly as follows: The desired protein’s cDNA sequence was
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A B
C D
β-Arrestin coding region
HaloTag coding region
CMV promotor
Kanamycin resistance
full promotor
(742 bases)
1st truncation
(121 bases)
2nd truncation
(73 bases)
3rd truncation
(66 bases)
Figure 8: Plasmid maps of four cloned β-arr2-HaloTag fusion constructs. (A)
Full CMV promotor length (742 bases). The promotors in (B-D) are
gradually truncated (121, 73, and 66 bases)
aplified by PCR from the above-mentioned sources. Cloning primers
for µ receptor and β-arr2 DNA were chosen in such a way that a 5‘
SgfI restriction site and a 3‘ PmeI restriction site were appended to
the protein-coding region. The expression vector plasmids contain
a lethal gene (barnase) in a locus between those very two restric-
tion enzymes. Digesting the expression vectors with SgfI and PmeI
removes the lethal gene and produces a linear DNA strand, which
was separated from the barnase-coding region by electrophoresis in a
1% agarose TAE gel. An analog procedure yields the protein-coding
PCR product with "sticky ends". The so treated complementary DNA
fragments were mixed at a 1:3 (vector:insert) molar ratio and ligated
by T4 DNA ligase. Purified ligation products were delivered into
competent E. coli for replication as described. Screening of success-
fully transformed E. coli was effected by means of antibiotic selection
(kanamycin). All cloned plasmid constructs used in this work were
sequenced (Eurofins Genomics, Ebersberg, Germany).
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2.2.5 Confocal Microscopy
Confocal microscopy was used to control transfection efficiency, ex-
pression, and cellular localization of fluorescent proteins. To this end,
HEK-293 cells were harvested, suspended in growth medium and
then seeded onto poly-D-lysin coated 24 mm glass coverslips in a 6-
well cell culture dish to an initial confluence of ∼ 30%. Cells were
then kept in an incubator at 37 ◦C in a 5% CO2 atmosphere for three
hours. Following this, cell were transfected with amounts of plasmid
DNA varying from 16 - 450 ng per well. Transfections were done
using Effectene transfection reagent according to the manufacturer’s
recommendations. Cells were kept in an incubator as described above
for 48 hours, with renewal of the growth medium after 24 hours.
The glass coverslips bearing the cells to be imaged were then mount-
ed in an Attofluor cell chamber (ThermoFisher Scientific) and onto
the microscope immediately before the experiment. During that time,
the cells were kept in measuring buffer. Depending on the fluores-
cent dyes used, the maximum imaging magnification was set in such
a way that the Nyquist criterion be met at all times. Cyan fluorescent
proteins (CFP and mTq2) were excited with a 442 nm diode laser,
yellow fluorescent proteins (YFP and Venus) were excited with a 514
nm argon laser. Optimum use of the detectors’ dynamic range was
ensured before imaging.
Images were recorded and stored in a Leica proprietary file format
(∗.lif). All image editing was done with a Fiji distribution of ImageJ
[193–195].
2.2.6 FRET experiments
FRET measurements were done through a Zeiss Axiovert 200 inverted
microscope. It was equipped with an oil immersion 63x objective lens
and a dual-emission photometric system (Till Photonics, Gräfelfing,
Germany). Setups very similar to this one have been used before
and described in the literature [61, 64]. Cover slips prepared as de-
scribed in section 2.2.1 were mounted onto the microscope shortly
before the experiment. The transfected cells were excited with light
from a polychrome IV (Till Photonics). The excitation light spectrum
was first capped by a dichroic long-pass beamsplitter at 460 nm and
after that narrowed down to 436 ± 10 nm by a band-pass filter. Illu-
mination during FRET measurements was set to 40 ms applied with
a frequency of 10 Hz.
Light emitted from the samples was split into acceptor and donor
beams by a dichroic long-pass beam splitter at 505 nm. Two band-
pass filters restricted the recorded emissions wavelengths (donor 480
± 20 nm; acceptor 535 ± 15 nm). Signals from cyan fluorescent pro-
teins (CFP and modified Turquoise 2 fluorescent protein (mTq2)) and
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yellow fluorescent proteins (YFP and Venus) were recorded simulta-
neously as well as the ratio of both (math = acceptordonor ). FRET ratios were
offline corrected for bleed-through of cyan fluorescent protein (CFP)
emission to the yellow fluorescent protein (YFP) channel and direct
excitation of YFP fluorophores (correction factors 0.85 and 0.12, re-
spectively) using Origin 9.
During FRET measurements, the cells were maintained in mea-
suring buffer and permanently superfused with said buffer using a
computer-assisted solenoid valve-controlled rapid superfusion device
(ValveLink 8.2, Automate Scientific). Fluorescence signals were de-
tected by photodiodes and digitalized using an analogue-digital con-
verter (Digidata 1440A, Axon Instruments). All data were recorded on
a PC running Clampex 10.3 software (Axon Instruments). Every array
of application of various concentrations of a ligand was succeeded
by the application of 10 µM DAMGO as a reference compound. In
order to obtain reliable concentration-response curve fits, every lig-
and was measured in at least six different concentrations. Every con-
centration of every ligand was usually measured at least five times
independently on at least three separate days. One exception were
experiments with antagonists, where three repeated measurements
showing no change in FRET signal were regarded sufficient.
2.2.7 Luciferase Complementation Assay
The µ receptor:β-arr luciferase complementation experiments were
conducted by Stefanie Meyer as part of her MD thesis (not published
yet).
On the day of the experiment, the cells in 96-well plates were incu-
bated with different concentrations of ligand for 12 min at 37 ◦C in
a 5% CO2 atmosphere. 100 µl/well of Bright-Glo Assay ReagentTM
(Promega, Mannheim, Germany) were added . The assay reagent con-
tains the luciferase substrate and also lyses the cells. To ensure com-
plete cell lysis and light adaptation the cells were incubated for an-
other 2 min inside the EnVision microplate reader.
Eluc activities were measured for 1 sec per well using an emission
filter detecting luminescence at 400-700 nm as a quantitative read-
out of receptor:β-arr interaction. On every plate, measurements were
done in duplicates. As a control to subtract background luminescence
FRET measuring buffer was used. 100 µM DAMGO served as a refer-
ence. All measurements were performed four times on different days.
2.2.8 BRET Assay
Cells for BRET experiments were prepared as described in 2.2.1. At
the beginning of the experiments, each well of a white flat-bottom
96-well microtiter plate (pureGradeTM, Brand GmbH, Wertheim, Ger-
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many) contained 90 µl of cells resuspended in Opti-MEM. 25 µl of
a 50 µM NanoGlo R© substrate stock (luciferase substrate; Promega,
Mannheim, Germany) were then added to each well, eventually re-
sulting in a 10 µM final concentration. The substrate was added to
the microtiter plates manually and it turned out that the time the
pipetting took was sufficient for maximum luciferase emission to oc-
cur (also see figure 14). Next, 12.8 µl of 10x concentrated stocks of
the desired opioid ligand concentrations were added to the wells.
Readout in the GloMax Discover plate reader was started immedi-
ately thereafter, usually resulting in a latency time from ligand addi-
tion to signal readout of ∼120 seconds for every single well. Mea-
surements were done in duplicates. Also, four wells of unlabeled
HaloTag acceptor constructs (i.e. without acceptor fluorophor) were
measured as a background control on every plate. Moreover, four
wells were stimulated with a saturating concentration of DAMGO
(100 µM), which then served as a reference for normalization for each
respective concentration-response curve. Every ligand was measured
in eleven concentration increments at least three times independently
on different experimental days.
Results were exported by the plate reader’s software to Microsoft
Excel files. Output variables were donor emission, acceptor emission
and BRET ratio, where
ratio =
acceptor emission
donor emission
.
2.2.9 Western Blot
Western blotting was performed according to the following scheme:
Cells were seeded in such a way that they reached 70-80% conflu-
ency on the day of cell lysis. If the target protein was to be extracted
from transiently transfected cells, transfection was done 48 hours in
advance in a 100 mm cell culture dish.
First, cells were washed with ice-cold DPBS and 1 ml of fresh
Laemmli sample buffer (see 2.1.4) was added to the cells. The plates
were stored on ice and slowly shaken for 20 minutes. After this, the
lysed cells were scraped off the dish and sonicated in a 1.5 ml Eppen-
dorf tube for one second. The sonicated lysates were stored on ice or
frozen at -20 ◦C for future use.
Quantification of protein contained in the lysates was effected by
means of the Pierce BCA protein assay kit according to the manu-
facturer’s protocol. The GloMax Discover plate reader was used for
colorimetric readout.
SDS gels were prepared in a BioRad electrophoresis cell (see sec-
tion 2.1.4) as follows. For the lower gel 13.5 ml H2O, 7.9 ml lower
buffer, 10.1 ml acrylamide, 15.75 µl TEMED, and 204.8 µl ammonium
persulfate (APS) were mixed and transferred to the casting stand. Iso-
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propanol was pipetted on top to ensure a smooth surface of the gel.
As soon as the gel was set, the isopropanol was removed and the up-
per gel mix (8.3 ml H2O, 3.3 ml upper buffer, 1.7 ml acrylamide, 13.2
µl TEMED, 132 µl APS) was transferred to the casting stand. A gel
comb was inserted and the upper gel polymerized within 15 minutes.
The volume of lysate loaded to each well was adjusted to yield
the desired amount of protein. The various amounts of protein used
varied between experiments and are pointed out in detail in the re-
spective results sections. Electrophoresis took place in fresh running
buffer at 80 V in the upper part and at 150 V in the lower part of the
gel. After completion of the electrophoresis, the gel was transferred to
filter paper soaked in Towbin buffer. The proteins were blotted onto a
Millipore Immobilon-P membrane in a BioRad semi-dry transfer cell
during 60 minutes at 15 V. The mebrane was activated beforehand ac-
cording to the manufacturer’s recommendations with methanol and
pre-soaked with Towbin buffer.
After blotting was finished, the filter was left in blocking buffer
on the shaker for one hour at room temperature. Subsequently, the
blocking buffer was discarded and the filter was incubated with the
primary antibody at 4 ◦C shaking overnight.
The following day, the gel was washed in wash buffer six times
for ten minutes each. Next, the gel was incubated with the secondary
antibody shaking for 60 minutes at room temperature. This was fol-
lowed by another washing step in analogy to the one described above.
Chemiluminescent imaging was done as indicated by the manufac-
turer of the detection reagent (see section 2.1.4).
2.2.10 HEK-Blue Reporter Gene Assay
To investigate whether and to what extent the opioids used in this
study could induce TLR4 signaling, a commercial reporter gene as-
say (HEK-Blue, InvivoGen) was implemented. This reporter gene as-
say was used before for similar experiments in the literature [189]. In
brief, activation of TLR4 in the cells will lead to increased production
of NF-κB, which in turn promotes the synthesis of a secreted em-
bryonic alkaline phosphatase (SEAP). SEAP will eventually cause a
special detection medium to change its color from red to blue, which
can be read out as a semiquantitative measure of receptor activation.
A TLR4-deficient, but otherwise identical cell line (HEK-Blue Null2)
served as a control.
Proper TLR4 signaling is dependent on the additional presence of
MD2, a secreted adaptor protein and CD14, which functions as a co-
receptor. Both proteins are stably expressed in the cell lines. The nat-
ural ligand of TLR4 is LPS, also known as endotoxin from the outer
membrane of Gram-negative bacteria. LPS was used as positive con-
trol in the experiments.
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For the TLR4 activation experiments, HEK-Blue hTLR4 and HEK-
Blue Null2 cells were grown to 50-80% confluency under conditions
described in 2.2.1. Cells were then washed cautiously with DPBS. This
DPBS was removed and fresh 2-5 ml of DPBS were added to the cells.
The flask was then put into the incubator at 37 ◦C for two minutes.
After that, the flask was tapped lightly to detach the cells. They were
suspended in the DPBS and counted. A suspension was prepared
to contain ∼140,000 cells/ml (HEK-Blue hTLR4) or 280,000 cells/ml
(HEK-Blue Null2) in HEK-Blue Detection medium. 20 µl of sample
solution or LPS as a positive control or sterile water as a negative
control, respectively were given into each well of a 96-well plate. Then,
180 µl of the prepared cell suspension were added to those wells,
resulting in a concentration of 25,000 cells per well (50,000 cells per
well in the case of HEK-Blue Null2 controls). An incubation time of
12-16 hours was needed for the SEAP to catalyze the color reaction.
After that time span, the extinction at 655 nm was determined using
a spectrophotometer (SpectraMax Plus 384).
2.2.11 Data Manipulation and Analysis
FRET experiments (section 2.2.6): All obtained signal amplitudes were
normalized to the signal amplitude elicited by 10 µM DAMGO in
each respective experiment. Normalized data points of correspond-
ing ligand concentrations were pooled and fit to a four-parameter sig-
moidal curve with the bottom set to zero; all other parameters were
fit freely. Luciferase complementation experiments (2.2.7): Emission
intensities were averaged and normalized to 100 µM DAMGO. Stan-
dard four-parameter sigmoidal curve fitting was done using Graph-
Pad Prism 6. Bottom was set to zero, all other parameters were fit
freely. For each ligand, four concentration-response curves were plot-
ted seperately. The pharmacological parameters Emax and EC50 were
averaged from the respective four independent fits.
BRET experiments (2.2.8): Unlabeled acceptor control BRET ratios
were subtracted from ligand-stimulated BRET ratios to control for
bleed-through from the donor into the acceptor channel. These cor-
rected ratio duplicates were plot independently for every ligand on
every plate. Four parameter sigmoidal curve fitting was performed
and the output bottom value was used to define zero when normal-
izing the data. Also, the data were normalized to their plate’s 100
µM DAMGO reference signal. Normalized data were fit again to a
four-parameter sigmoidal curve with bottom fixed at zero; all other
parameters were fit freely.
Calulation of ligand bias was done largely as described by Kenakin
et al. [166]. In brief, the concentration-response data were fitted to
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the operational model of pharmacological agonism by Black and Leff
[164] according to the following equation:
response =
Em[A]nτn
[A]nτn + ([A] + KA)n
,
where Em is the maximum response of the system, [A] is the agonist
concentration, n is the transducer slope, KA is the agonist equilib-
rium dissociation constant and τ is the ratio [Rt]/KE, with [Rt] being
the receptor density and KE being the intrinsic efficacy of the ago-
nist for one specific signaling pathway. As always, curve-fitting was
done with GraphPad Prism 6. Standard output parameters were τ,
KA, log τ, log KA, and their respective standard errors and confidence
intervals. The software was additionally programmed to fit the de-
sired transduction coefficient log (τ/KA) as a parameter of its own.
Curve-fitting was performed like this for all ligands and all signal-
ing pathways seperately. Thereafter, ∆ log(τ/KA) values were calcu-
lated as the difference between log(τ/KA)ligand and log(τ/KA)re f erence.
The difference between ∆ log(τ/KA)pathway1 and ∆ log(τ/KA)pathway2
returns ∆∆ log(τ/KA) for any two signaling pathways and each lig-
and. As a slight aberration from the approach in [166] the propagation
of standard errors was approximated as follows:
error =
√
errorA2 + errorB2
for each arithmetic operation. The final standard errors were trans-
formed into confidence intervals for depiction in the bias plots (see
section 3.7).
3
R E S U LT S
3.1 optimization of a g i fret sensor
The activation of Gi at the µ receptor was quantitatively assesed by
a FRET-based sensor as described in section 2.2.6. In order to ensure
proper expression of all three G protein subunits, confocal images of
HEK cells transfected with the µ receptor and the Gi sensor trimer
in the same way as for the FRET experiments were taken. figure 9
shows the expression of both fluorophores (mTq2 and Venus), i.e. the
protein subunits they were genetically attached to (Gα and Gγ, re-
spectively). Both subunits are located near the cell membrane. This
makes the existence of a functional trimer reasonable, thus suggest-
ing also proper expression of the non-fluorescent β subunit. Relative
abundance of Venus over mTq2 may be derived from the images, al-
though no quantification to this end was done. This finding would
be in line with the plasmid’s authors claiming an approximately 3:1
expression ratio (upstream:downstream of the IRES sequence) [196].
Figure 9: Confocal image of HEK-293 cells transfected with the Gi trimer
plasmid; left: mTq2 channel, right: Venus channel. Scale bars rep-
resent 25 µm.
The search for optimal DNA amounts of receptor and G protein
for transfection was an iterative process. When transfecting with 2.5
µg of each plasmid per 6-well plate, a loss in normalized FRET ratio
of more than 20% could be achieved (figure 10, bottom red trace). In-
cremental addition of ligand concentrations led to ever more loss in
FRET ratio. Final application of a saturating DAMGO concentration
(10 µM) gave the reference signal for this very experiment. The yellow
and blue traces show the corresponding signals from the Venus and
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mTq2 channels. The two signals developing in an antiparallel manner
was another proof of a functioning FRET system: loss in signal from
one fluorophore translates into gain of the other and vice versa. As
the α and the βγ subunits move away from each other or even disso-
ciate upon activation [64], incremental loss in FRET ratio during the
course of the experiments was reasonable, too.
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Figure 10: Exemplary traces of a single FRET measurement. All three traces
were recorded simultaneously. Bars indicate the addition of lig-
and during that period of time. Note that the depicted donor and
acceptor traces were not yet corrected for bleed-through and di-
rect excitation, whereas the FRET ratio trace was calculated from
corrected values.
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3.2 ligand-dependent activation of g i at the µ recep-
tor
With the described sensor at hand, the pharmacological dynamics of
Gi activation by 17 opioid ligands were examined. The data sufficed
to cover the full concentration-response range for all of the opioids.
Standard sigmoidal four parameter fit allowed for the following clas-
sification of the ligands into subgroups:
full agonists
DAMGO, buprenorphine, fentanyl, L-methadone, piritramide,
remifentanil, sufentanil
partial agonists
hydromorphone, M-6-G, morphine, oxycodone, pethidine, tapen-
tadol, tilidine, tramadol
antagonists
naloxone, naltrexone
Graphed concentration-response curves are given, grouped in the
same manner: full agonists (figure 11) and partial agonists / antago-
nists (figure 12). Graphs were derived from standard four-parameter
sigmoidal fits. The full agonists cover a potency range of around 2.5
log levels, with logEC50s ranging from -8.48 (remifentanil) to -6.12
(piritramide). The reference compound DAMGO lies in between
(logEC50=-7.43).
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Figure 11: Concentration-response curves of full agonists for Gi activation.
Error bars denote SEM, n≥3.
For four opioids a plateau signal could not be reached, which adds
extra uncertainty to their respective Emax and EC50 values. Pethidine,
tapentadol, and tramadol turned out to be rather low-potency ago-
nists (EC50 42500 and 138000 nM). Higher ligand concentrations than
the ones used could not be prepared for the experiments. Buprenor-
phine has high potency (179 nM) and very high receptor binding
3.2 g i activation 45
re
lat
ive
 re
sp
on
se
no
rm
ali
ze
d 
to
 1
0 
µM
 D
AM
GO
-11 -10 -9 -8 -7 -6 -5 -4 -3 -2
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
tramadol
oxycodone
M6G
hydromorphone
DAMGO
naltrexon
log ligand concentration [M]
-11 -10 -9 -8 -7 -6 -5 -4 -3 -2
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
tilidine 
tapentadol
pethidine
morphine
DAMGO
naloxone
re
lat
ive
 re
sp
on
se
no
rm
ali
ze
d 
to
 1
0 
µM
 D
AM
GO
Figure 12: Concentration-response curves of DAMGO and partial agonists
for Gi activation. Error bars denote SEM, n≥3.
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affinity, which made it difficult to determine its maximum response
relative to a reference substance (also see Discussion, section 4.1). De-
tailed pharmacological properties of all ligands are given in table 2.
Emax EC50 logEC50
(S.E.M.) [nM] (S.E.M.)
DAMGO
1.01 37.5 −7.43
(0.07) (0.15)
Buprenorphine∗ < 1 179 −6.75
− −
Fentanyl
0.99 38.1 −7.42
(0.02) (0.04)
Hydromorphone
0.57 31.7 −7.50
(0.03) (0.15)
M6G
0.85 290 −6.54
(0.12) (0.40)
L-Methadone
1.03 227 −6.65
(0.03) (0.09)
Morphine
0.79 412 −6.39
(0.14) (0.46)
Naloxone
0.0 − −
− −
Naltrexone
0.0 − −
− −
Oxycodone
0.77 1610 −5.79
(0.06) (0.17)
Pethidine∗ 0.98 26900 −4.57
(0.21) (0.62)
Piritramide
1.08 758 −6.12
(0.12) (0.27)
Remifentanil
1.1 3.32 −8.48
(0.03) (0.08)
Sufentanil
0.99 4.22 −8.38
(0.07) (0.18)
Tapentadol∗ > 0.6 42500 −3.86
− (0.98)
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Emax EC50 logEC50
(S.E.M.) [nM] (S.E.M.)
Tilidine
0.74 25700 −4.59
(0.11) (0.47)
Tramadol∗ > 0.7 138000 −3.86
− (0.98)
Table 2: Pharmacological properties of 17 opioid ligands for the activation
of Gi. (∗) Maximum agonist response could not be obtained, corre-
sponding EC50 values are an approximation.
3.3 ligand-dependent recruitment of β-arrestins 1 and
2 to the µ receptor (luciferase complementation)
Data on β-arr 1 and 2 recruitment were determined by a luciferase
complementation assay, which was performed by Stefanie Meyer as
part of her MD thesis (unpublished work). An overview of the data
is given in table 12 in section A.2 of the appendix. These data served
in part as the basis for the calcuation of ligand bias performed in this
work.
3.4 implementation of a bret-based β-arrestin 2 recruit-
ment assay
In order to implement the NanoBRET
TM
assay as a tool for measuring
µ receptor:β-arr2 interaction, first the coding regions of both the re-
ceptor and the arrestin were cloned into the respective vectors. This
was mainly done by Ulrike Zabel. As pointed out in section 2.2.4,
the empty cloning vectors came in different configurations such that
one can position the Nluc or HaloTag at the N or C terminus of
the respective target protein. Additionally, the HaloTag cloning vec-
tors came with different promotor truncations for alledged control
of protein expression. The µ receptor was cloned only to have the
Nluc attached to the C terminus. The N terminus of the receptor lies
outside the cell and is therefore too far apart from a possibly bind-
ing β-arr for BRET to occur. β-arr2 was cloned with the HaloTag at-
tached to both termini and with all four promotor truncations, each.
No constructs with the luciferase at the arrestin and the HaloTag at
the receptor were created. Eventually, nine plasmid constructs were
created to screen for an ideal BRET pair: one receptor-luciferase(C),
four HaloTag(N)-arrestins, and four arrestin-HaloTag(C)s. Successful
cloning was confirmed by plasmid sequencing (data not shown).
The effect of the truncated CMV promotors on protein expression
levels was controlled by Western blotting from cell lysates of HEK
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Figure 13: Western blot of the four different β-arr2 plasmid constructs with
an N-terminal HaloTag. Total protein amount per well: 70 µg.
Digital contrast enhancement and background subtraction was
performed.
cells transfected with 2 µg plasmid DNA per 100 mm dish 48 hours
prior to cell lysis. Western blots were done as explained in section 2.2.9
using an antibody against the HaloTag. The constructs with the full
promotor showed strong protein expression, those with the longest
truncation were found to cause expression levels still detectable in
the blots. The plasmids with the two shortest promotor versions (73
and 66 bases) did not cause any traceable protein expression. These
findings were confirmed in repeated blots for both C and N termi-
nally attached HaloTags. figure 13 shows an exemplary blot from 70
µg total protein per well of the four N terminal constructs.
With these results at hand, the decision for the best HaloTag/ar-
restin fusion protein had to be made choosing from the four con-
structs that were expressed at all in the cells (pFC14K-β-arr2-HaloTag,
pFC15K-β-arr2-HaloTag, pFN21K-HaloTag-β-arr2, pFN22K-HaloTag-
β-arr2). To this end, BRET experiments were performed with cells
transfected with 0.2 µg pFC32K-Nluc-OPRM, 2.0 µg of the arrestin /
HaloTag construct in question, and 1.0 µg GRK2. The receptor kinase
was co-transfected to ensure sufficient receptor phosphorylation. Gen-
eral assay preparations were done as described in section 2.2.8. After
a first read-out in the plate reader without ligand added, DAMGO
was added to a resulting concentration of 100 µM. Figure 14 shows
the kinetics of the corrected BRET signal of all four plasmid pairs.
It turned out that the constructs with the full promotor caused a
steeper and higher increase in BRET ratio than the plasmids with
the 121 bases truncated promotors. Moreover, the full signal was
achieved in the first measurement after ligand addition for all four
constructs. The time between manual ligand addition and first read-
out varied slightly from experiment to experiment, but generally was
in the range of 50 to 60 seconds. These findings were confirmed in
repeated experiments (data not shown).
To eventually choose one HaloTag construct as BRET interaction
partner, repeated endpoint measurements were performed with pFC14K-
β-arr2-HaloTag and pFN21K-HaloTag-β-arr2. BRET ratios were cor-
rected and normalized to the baseline signal before ligand addition.
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Figure 14: Time course of the BRET ratios of four different β-arr2-HaloTag
plasmid constructs used for transfection. Addition of a saturating
concentration of DAMGO took place after acquisition of the data
point at time point zero. Error bars indicate SD, n=2.
By this approach, the BRET pair with the highest dynamic range, i.e.
largest difference between lowest and highest detectable signal, could
be identified. Results are shown in figure 15. Both BRET pairs show
maximum responses of around 3-fold over baseline. Even if pFC14K-
β-arr2-HaloTag presented with slightly more scatter than pFN21K-
HaloTag-β-arr2, the former was eventually chosen as BRET acceptor
due to its higher signal intensity.
As a last step of sensor optimization the ratio of used plasmid DNA
was varied. The following ratios of receptor:arrestin were under inves-
tigation:
• 0.02 : 2.0
• 0.1 : 2.0
• 0.2 : 2.0
• 1.0 : 2.0 and
• 1.0 : 1.0
The highest signal could be achieved with 0.1 and 0.2 µg arrestin
with no major differences between the two. When approaching a 1:1
ratio, signal intensities decreased markedly. However, decreasing the
amount of receptor DNA to only 0.02 µg did not further enhance
signal quality (detailed data not shown). Eventually, the transfection
ratio with 0.2 µg receptor and 2.0 µg arrestin was maintained as it
produced robust signals throughout the optimization process and no
substantial improvements seemed possible.
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Figure 15: Scatter plot of maximum BRET responses to a saturating
DAMGO concentration of 100 µM. Error bars indicate SD, n=6.
3.5 ligand-dependent recruitment of β-arrestin 2 to
the µ receptor (bret)
With the optimized BRET assay at hand, ligand and concentration-
dependent recruitment of β-arr 2 to the µ receptor was investigated
in detail. Since there were supply shortages for tilidine, full datasets
are available for 16 opioids. By their capability to bring the arrestin
to the receptor, the opioids can be categorized as follows:
full agonists and superagonists
DAMGO, fentanyl, L-methadone, pethidine, remifentanil, sufen-
tanil, tapentadol.
partial agonists
hydromorphone, M-6-G, morphine, oxycodone, piritramide, tra-
madol.
antagonists
buprenorphine, naloxone, naltrexone.
With efficacies higher than the full-agonist reference DAMGO, L-
methadone (Emax=1.13), remifentanil (Emax = 1.20), and tapentadol
(Emax = 1.20) qualified as super-agonists. However, remifentanil was
the only one among those three with markedly higher potency than
DAMGO (logEC50 -7.53 vs. -6.98). The full agonists covered a wide
range of potencies from from pethidine (logEC50 = -3.94) to sufen-
tanil (logEC50 = -8.17) with DAMGO in between (logEC50 = -6.98). All
the partial agonists presented with rather high efficacies with oxy-
codone being the weakest (Emax=0.68). Solely tramadol fell out of line
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Figure 16: Concentration-response curves of full agonists and superagonists
for β-arr2 recruitment to the µ receptor. Data are derived from
BRET experiments, GRK2 was overexpressed in the cells. Error
bars denote SEM, n=2.
(Emax=0.34). Antagonists were naloxone and naltrexone, as expected,
and buprenorphine.
Signal plateaus could be obtained for all agonists, yet again stan-
dard errors increase with decreasing potency and efficacy. Full con-
centration-response curves can be found in figure 16 for full agonists
and superagonists and in figure 17 for partial agonists and antago-
nists. As opposed to the Gi data in section 3.2, β-arr BRET data were
not pooled. The graphed data therefore represent only one of usually
three independent experiments. Curves are derived from standard
four parameter sigmoidal fits.
A complete overview of the pharmacological properties of the 16
opioids can be found in table 3. Note that the values given there
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Figure 17: Concentration-response curves of partial agonists and antago-
nists for β-arr2 recruitment to the µ receptor. Data are derived
from BRET experiments, GRK2 was overexpressed in the cells.
DAMGO is shown for orientation purposes. Error bars denote
SEM, n=2.
3.5 β-arrestin 2 recruitment (bret) 53
are means from all individual experiments for each ligand and might
therefore not entirely match the shown concentration-response curves.
Emax EC50 logEC50
(S.E.M.) [nM] (S.E.M.)
DAMGO
0.98 106 −6.98
(0.10) (0.27)
Buprenorphine
0.0 − −
− −
Fentanyl
1.05 42.0 −7.38
(0.14) (0.30)
Hydromorphone
0.72 32.8 −7.48
(0.12) (0.30)
M6G
0.91 313 −6.51
(0.32) (0.54)
L-Methadone
1.13 233 −6.63
(0.09) (0.19)
Morphine
0.83 390 −6.41
(0.09) (0.20)
Naloxone
0.0 − −
− −
Naltrexone
0.0 − −
− −
Oxycodone
0.68 1090 −5.96
(0.10) (0.38)
Pethidine
1.14 116000 −3.94
(0.66) (1.72)
Piritramide
0.88 117 −6.93
(0.09) (0.26)
Remifentanil
1.20 29.2 −7.53
(0.09) (0.16)
Sufentanil
0.97 6.75 −8.17
(0.11) (0.21)
Tapentadol
1.20 265 −6.58
(0.20) (0.47)
54 results
Emax EC50 logEC50
(S.E.M.) [nM] (S.E.M.)
Tilidine #
Tramadol
0.34 78800 −4.10
(0.16) (1.35)
Table 3: Pharmacological properties of 16 opioid ligands for β-arr2 recruit-
ment. GRK2 was overexpressed in the cells. Error bars indicate SEM,
n=3. # no data acquired due to ligand supply shortages.
Initially, these experiments were thought as a reproduction of the
data already obtained by Stefanie Meyer with the luciferase comple-
mentation approach (table 12). The intention was to already have
a reliable dataset for comparison when implementing the BRET as-
say. However, marked differences between the two datasets could be
found: Almost throughout, efficacies were increased (higher Emax) as
were potencies (lower logEC50). Also, no superagonists were found
in the luciferase complementation data. Probably most strinkingly, in
the luciferase complementation data, there were four antagonists next
to naloxone and naltrexone (buprenorphine, tapentadol, tilidine, and
tramadol). In the BRET assay, of these four only Buprenorphine re-
mained, with tapentadol even acting as a superagonist. There were
no data for tilidine in this assay, as was pointed out earlier.
To further elucidate these findings and to make the results more
comparable, all BRET experiments were performed again without co-
transfection of GRK2. The cell lines provided to us for the luciferase
complementation experiments did not overexpress the kinase. GRK2
expression was not different compared to the HEK cells used in the
BRET experiments. This was confirmed by repeated western blots, as
shown in figure 18.
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Figure 18: (A) Western blots of GRK2 expression in native HEK-293 and
HEK-Eluc-OPRM1-β-arr2 cells. Lysates of three separate experi-
ments with both cell lines were blotted side by side. β-actin was
used as housekeeping protein for comparison. Total protein load
was adjusted to 50 µg in both wells. Digital contrast enhancement
and background correction was performed for better visibility in
print after quantification. (B) Quantifiction of (A); intensities of
GRK2 relative to β-actin for each corresponding pair of values
are shown. Bars denote mean ± SD. Paired, two-sided t test, n=6,
p=0.3433
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3.6 influence of grk2 overexpression on the recruit-
ment of β-arrestin 2
The following experiments were performed entirely in analogy to
those in section 3.5 except for the here omitted over-expression of
GRK2. From the results, the opioids could be categorized as follows:
full agonists
DAMGO.
strong partial agonists
fentanyl, L-methadone, remifentanil, sufentanil.
weak partial agonists
hydromorphone, morphine, oxycodone, pethidine, piritramide,
tapentadol.
antagonists
buprenorphine, naloxone, naltrexone, tramadol.
DAMGO as the reference compound was the only full agonist (by
definition). Classified as strong partial agonists were ligands with an
Emax > 0.5. All which met this criterion were full agonists or super-
agonsists in the experiments where GRK2 was overexpressed. The re-
mainder of substances fell within the group of weak partial agonists;
tramadol turned into an antagonist. Sufentanil again had the highest
potency of all ligands (logEC50=- 7.81). The other strong partial ago-
nists were close to DAMGO in this respect (logEC50=-6.13), the weak
partial agonists all had lower potencies (morphine: logEC50=-6.20 to
pethidine: logEC50=-3.41).
Due to prolonged supply problems, no data were obtained for
M-6-G and tilidine. The corresponding concentration-response curves
are shown in figure 19 (strong partial agonists), figure 20 (weak par-
tial agonists), and figure 21 (antagonists). Again, individual experi-
ments for each ligand were repeated at least three times, while the
graphs only depict duplicate values from single experiments.
Overall, these data corresponded very well with those from the lu-
ciferase complementation assay (see table 12 in the appendix), which
presumably took place in a comparable cellular proteomic environ-
ment. One noteworthy difference was tapentadol, which acted as a
partial agonist (Emax=0.74) in the BRET assay while manifesting it-
self as an antagonist in earlier experiments. Detailed pharmacological
properties of all tested ligands are given in table 4.
To make the influence of GRK2 overexpression vs. endogenous ex-
pression more plastic, Emax and EC50 values from the presented BRET
experiments with and without GRK2 overexpression were summa-
rized in figure 22. As for the maximum responses, all opioids pre-
sented with higher Emax values with GRK2 overexpression than with-
out (figure 22A). Exceptions are, of course, DAMGO, which, as the
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Figure 19: Concentration-response curves of DAMGO and strong partial ag-
onists for recruitment of β-arr2. Data stem from BRET experi-
ments, GRK2 was not overexpressed in the cells. Error bars de-
note SEM, n≥3
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Figure 20: Concentration-response curves of DAMGO and weak partial ago-
nists for recruitment of β-arr2. Data stem from BRET experiments,
GRK2 was not overexpressed in the cells. Error bars denote SEM,
n≥3
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Figure 21: Concentration-response curves of DAMGO and antagonists for
recruitment of β-arr2. Data stem from BRET experiments, GRK2
was not overexpressed in the cells. Error bars denote SEM, n≥3
reference compound has an Emax of 1 in all experiments by defini-
tion and the antagonists buprenorphine, naloxone, and naltrexone
(all zero). Tramadol was turned from an antagonist under endoge-
nous GRK2 expression into a partial agonist where the kinase was
overexpressed (Emax=0.34). Tapentadol even went from partial agonist
to superagonist (Emax=0.74 vs. Emax=1.20). The situation was compa-
rable when looking at efficacies (figure 22B). It was only pethidine
where GRK2 overexpression did not cause a left-shift of efficacy as
compared to endogenous kinase expression levels. The left-shift is
between one and 1.5 log units throughout the datasets. In summary,
changing the expression levels of GRK2 in the cells was sufficient to
significantly change the behavior regarding β-arr2 recruitment of all
investigated opioids.
Emax EC50 logEC50
(S.E.M.) [nM] (S.E.M.)
DAMGO
0.97 749 −6.13
(0.09) (0.21)
Buprenorphine
0.0 − −
− −
Fentanyl
0.73 96.4 −7.02
(0.11) (0.30)
Hydromorphone
0.08 208 −6.68
(n=6) (0.07) (0.34)
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Emax EC50 logEC50
(S.E.M.) [nM] (S.E.M.)
M6G #
L-Methadone
0.80 886 −6.05
(0.08) (0.21)
Morphine
0.28 632 −6.20
(0.10) (0.64)
Naloxone
0.0 − −
− −
Naltrexone
0.0 − −
− −
Oxycodone
0.05 3090 −5.51
(n=5) (0.04) (0.38)
Pethidine
0.21 393000 −3.41
(n=5), no plateau (0.16) (0.72)
Piritramide
0.08 338 −6.47
(n=6) (0.12) (0.77)
Remifentanil
0.74 191 −6.72
(0.07) (0.16)
Sufentanil
0.56 15.4 −7.81
(0.11) (0.27)
Tapentadol
0.74 8000 −5.10
(0.15) (0.39)
Tilidine #
Tramadol
0.0 − −
− −
Table 4: Pharmacological properties of 15 opioid ligands for β-arr2 recruit-
ment. Data originate from BRET experiments, GRK2 was not over-
expressed in the cells. Error bars indicate SEM, n=3 unless denoted
otherwise. # no data acquired due to ligand supply shortages.
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Figure 22: Changes in Emax (A) and EC50 (B) values from BRET experiments
with and without GRK2 overexpression. Bars indicate mean and
SEM of the calculated differences between the respective values
with and without GRK2 overexpression, n=3. GRK2over: values
from cells overexpressing GRK2; GRK2end: values from cells with
endogenous GRK2 expression
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3.7 calculation of biased agonism between g i , β-arrestin
1 , and β-arrestin 2
The abundance of pharmacological data collected to this point al-
lowed for further analysis of signaling properties of the µ receptor.
As introduced earlier, agonism bias is a concept which is capable of
providing valuable insights in the entirety of signaling starting from a
certain receptor. For the approach favored here [166] it was necessary
to fit concentration-response data to the operational model of phar-
macological agonism. Details were explained in section 2.2.11. Out-
put fit values were, among others τ and KA, which, as a compound
parameter log τKA served as the basis for further calculations. log
τ
KA
values were first compared between ligand and reference compound
within each pathway (resulting in ∆ log τKA , data not shown) and then
pairwise between pathways (∆∆log τKA ). ∆∆ log
τ
KA
is a numerical mea-
sure on a log scale for a ligand’s tendency to prefer the activation of
one pathway over another. Positive numbers indicate bias towards the
first signaling pathway and vice versa, thus making the signs of the
numbers subject to convention. These calculations were performed
on the basis of the FRET Gi data and the β-arr 1 and 2 recruitment
data from the luciferase complementation experiments. An overview
on ∆∆log τKA values for all the opioids is given in table 5.
Gi − β-arr1 Gi − β-arr2 β-arr1 − β-arr2
DAMGO 0 (−) 0 (−) 0 (−)
Buprenorphine∗ 1 (−) 1 (−) −
Fentanyl −1.27 (1.61) −0.37 (0.76) 0.91 (1.67)
Hydromorphone 0.19 (4.66) 0.42 (1.70) 0.23 (4.70)
M6G # 0.40 (3.00) #
L-Methadone −0.67 (0.70) 0.32 (0.60) 0.34 (0.83)
Morphine 0.93 (3.09) 0.42 (1.44) −0.51 (3.20)
Naloxone − − −
Naltrexone − − −
Oxycodone 1.00 (4.32) 0.37 (1.51) −0.62 (4.34)
Pethidine 0.63 (2.35) 0.52 (1.47) −0.11 (2.61)
Piritramide −0.06 (0.92) −0.62 (0.82) −0.56 (1.13)
Remifentanil 1.35 (1.21) 0.88 (0.56) −0.47 (1.22)
Sufentanil −0.55 (0.75) −0.76 (0.66) −0.21 (0.87)
Tapentadol∗ 1 (−) 1 (−) −
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Gi − β-arr1 Gi − β-arr2 β-arr1 − β-arr2
Tilidine∗ 1 (−) 1 (−) −
Tramadol∗ 1 (−) 1 (−) −
Table 5: ∆∆ log τKA values of 17 opioid ligands between Gi signaling and
β-arr1 and β-arr2 recruitment. GRK2 was not overexpressed in the
cells. Numbers in brackets indicate 95% CI. ∗∆∆ log τKA values for
bias between Gi and either β-arr were arbitrarily set to 1 (see text).
#No data for β-arr1 recruitment due to shortages in ligand supply.
Significant ligand bias was assumed only if ∆∆ log τKA and its com-
plete 95% CI lied above or below zero. CIs were derived from approx-
imations of propagated standard errors. Visualizations of ∆∆ log τKA
plus CI (bias plots) help to identify significant ligand bias more easily.
figure 23 shows a bias plot for a selection of opioids with significant
ligand bias.
From our data, only sufentanil appeared to show bias towards
the recruitment of β-arr2 (∆∆ log τKA = -0.76 ± 0.66). Bias between
Gi and β-arr1 pointed in the same direction but was not significant
(∆∆ log τKA = -0.55 ± 0.75). Remifentanil was biased towards Gi ac-
tivation compared to both β-arrs 1 and 2 (∆∆ log τKA = 1.35 ± 1.21
and ∆∆ log τKA = 0.88 ± 0.56, respectively). Four opioids in the ex-
perimental set at hand eluded the exact calculation of ligand bias:
buprenorphine, tapentadol, tilidine, and tramadol. These four did not
recruit any arrestins, thus leaving them with zero potency and miss-
ing efficacy values. This rendered calculation of a bias factor impossi-
ble. They were arbitrarily assigned ∆∆ log τKA values of 1, expressing
their obvious bias towards Gi. After all, ∆∆ log τKA values lie on a log
scale, i.e. a value of 1 translates into tenfold stronger activation of
one pathway on a linear scale. DAMGO as the reference substance
has ∆∆ log τKA s of zero by definition in all signaling pathway compar-
isons. Generally, there was no bias between the two arrestins within
a single ligand. A complete bias plot including all non-significant val-
ues is given in figure 37 of the Appendix.
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Figure 23: Bias plot of selected opioid agonists. Bias was calculated based
on FRET Gi data and β-arr recruitment data from luciferase com-
plementation. GRK2 was not overexpressed in the cells. Positive
∆∆ log τKA values indicate bias towards the signalling pathway
named first in the respective legend, and vice versa. Error bars
denote 95% CI. Values marked with an asterisk (*) are arbitrarily
assigned to 1. Here, bias could not be calculated due to missing
activity in both β-arr pathways (see text for details).
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3.8 influence of grk2 overexpression on agonism bias
Results described in detail in section 3.6 suggested a key influence
of GRK2 expression levels on the pharmacodynamics of β-arr recruit-
ment. One would expect this to also change agonism bias fundamen-
tally. Ligand bias in section 3.7 was calculated from data derived from
cells expressing endogenous levels of GRK2. However, the pharmaco-
dynamics of β-arr2 (not β-arr1) recruitment under GRK2 overexpres-
sion have already been described in section 3.5. Thus, it stood to rea-
son to calculate agonism bias for this set of data as well. Operational
model fitting and calculation of ligand bias was done as described
above. As there were no data on β-arr1 recruitment under GRK2 over-
expression to begin with, only one pairwise comparison per ligand
was calculated. figure 24 shows the corresponding bias plot.
∆∆ log τKA 95% CI
DAMGO 0 −
Buprenorphine∗ 1 −
Fentanyl −0.52 1.18
Hydromorphone −0.09 1.48
M-6-G −0.11 1.56
L-Methadone −0.71 1.17
Morphine 0.04 1.31
Naloxone −
Naltrexone −
Oxycodone −0.10 1.56
Pethidine −0.14 1.25
Piritramide −1.22 1.35
Remifentanil 0.22 1.01
Sufentanil −0.30 1.22
Tapentadol −1.18 1.25
Tilidine #
Tramadol 1.50 2.78
Table 6: ∆∆ log τKA values of 16 opioid ligands between Gi signaling and
β-arr2 recruitment. ∗∆∆ log τ/KA values were arbitrarily set to 1
(see text). #No data due to shortages in ligand supply.
Most of the significant bias was abolished by the overexpression of
GRK2. ∆∆ log τKA of Sufentanil is still slightly negative, but far from
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Figure 24: Bias plot of selected opioid agonists in cells overexpressing GRK2.
Bias was calculated based on FRET Gi data and β-arr2 recruit-
ment data from BRET experiments. Positive ∆∆ log τ/KA values
indicate bias towards the signalling pathway named first in the
respective legend, and vice versa. Error bars denote 95% CI. Val-
ues marked with an asterisk (*) are arbitrarily assigned to 1 (for
details, see text).
significance (-0.30 ± 1.22). The same was true, under inverse signs for
Remifentanil (∆∆ log τKA = 0.22 ± 1.01). Tapentadol (∆∆ log τKA = -1.18± 1.25) and Tramadol (∆∆ log τKA = 1.50 ± 2.78) appeared non-biased
(i.e. balanced) with the overexpression of the kinase; for Tilidine there
were no β-arr2 recruitment data. Solely Buprenorphine did not elicit
any β-arr2 recruitment and was therefore again considered to be bi-
ased towards Gi with an assigned ∆∆ log τKA of 1.
3.9 implementation of a reporter gene assay for tlr4
signaling
An involvement of TLR4 in undesired effects caused by opioids has
been discussed in recent literature as pointed out in figure 1.6. To in-
vestigate whether and to what extent the opioids used in this study
could induce TLR4 signaling, a commercial reporter gene assay (HEK-
Blue, InvivoGen) was implemented. In short, activation of TLR4 in
the cells will lead to increased production of NF-κB, which in turn
promotes the synthesis of a SEAP. SEAP will eventually cause a spe-
cial detection medium to change its color from red to blue, which
can be read out as a semiquantitative measure of receptor activation.
A TLR4-deficient, but otherwise identical cell line (HEK-Blue Null2)
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Figure 25: Photograph of an exemplary HEK-Blue assay microtiter plate.
Some wells were treated with the positive control LPS, which
causes the medium to turn blue.
served as a control. The implementation of the assay was success-
ful after a few attempts; figure 25 Shows an experiment in a 96-well
microtiter plate. Wells that were exposed to 10 ng/ml LPS changed
their color to blue after an incubation period of 12 hours (A7-D9).
Wells containing Null-cells did not turn blue, neither without (E1-H5
on the plate) nor with (A10-D11) addition of LPS.
To begin with, a subset of opioids were then tested with this assay:
DAMGO, fentanyl, sufentanil, tramadol, piritramide, and morphine.
Water and LPS served as negtive and positive control, respectively. As
can be seen from figure 26, DAMGO elicited some signal (around 14 of
the LPS signal). The other tested opioids did not cause any detectable
response, neither did water.
In parallel to these first experiments the technical processes sur-
rounding the conduct of the assay were further refined. Special fo-
cus was laid on the adherence to strict endotoxin-free procedures.
This was eventually ensured by the use of an limulus amebocyte
lysate (LAL) gel clot test (Lonza, Basel, Switzerland), which was sen-
sitive up to a concentration of 0.06 EU/ml. By this method, contam-
ination with endotoxin could effectively be ruled out for all media,
buffers, and ligand solutions used.
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Figure 26: Box plot of optical absorption values for several opioid ligands in
an early HEK-Blue assay. Boxes and whiskers denote interquartile
range and complete range, respectively; n=8.
3.10 activation of tlr4 by opioid ligands
With the assay set up as described in section 3.9, structured testing
of all used opioid ligands was initiated. To this end, opioids were
used in concentrations which would be considered saturating in the
context of the µ receptor. Again, 10 ng/ml LPS and water were used
as controls. Data were normalized to the maximum LPS signal from
each plate in order to make the results comparable between experi-
ments. However, it turned out that in repeated independent measure-
ments no more signal could be evoked apart from the LPS reference.
Thawing of new cell batches and preparation of fresh ligand stock
solutions did not change this finding. figure 27 shows an example
of such an experiment. In conclusion it must be assumed that with-
out external endotoxin contamination, opioids do not elicit TLR4 re-
sponse detectable with this assay.
68 results
Ab
so
rp
tio
n 
at
 6
35
 n
m
wa
ter
LP
S 1
0 n
g/m
l
Na
ltre
xon
 20
0 µ
M
Na
lox
on
 10
0 µ
M
Tili
din
e 1
 m
M
Hy
dro
mo
rph
on
e 1
 m
M
Mo
rph
ine
 10
0 µ
M
M6
G 1
 µM
Tap
ent
ad
ol 1
00
 µM
Fe
nta
nyl
 10
 µM
Pe
thid
ine
 10
 m
M
Re
mif
ent
ani
l 10
0 µ
M
L-M
eth
ad
on
e 2
00
 µM
Su
fen
tan
il 1
 µM
DA
MG
O 1
00
 µM
Pir
itra
mid
 1 
mM
Ox
yco
do
ne 
1 m
M
Tra
ma
do
l 10
0 µ
M
Bu
pre
no
rph
ine
 20
 µM
0.0
0.1
0.2
0.3
0.8
0.9
1.0
Figure 27: Box plot of optical absorption values for several opioid ligands
in a HEK-Blue assay performed under endotoxin-free conditions.
Values are normalized to the mean LPS response. Boxes and
whiskers denote interquartile range and complete range, respec-
tively; n=8.
4
D I S C U S S I O N
In the work at hand, a total of 17 opioid ligands were thoroughly in-
vestigated with regard to signaling processes on a molecular level
occurring directly at the µ receptor. Three distinct pathways were
studied, namely the activation of the inhibitory G protein Gi and the
recruitment of both β-arrestins. In addition to that, expression levels
of the central mediating protein for β-arr recrutiment, GRK2, were
varied to determine their influence on the recruitment. The set of opi-
oids reflected upon here mainly consisted of opioid agonists which
are used in clinical routine. In order to have a full spectrum of ligands,
two µ receptor antagonists, naloxone and naltrexone, were included
as well. Furthermore, the main active metabolite of morphine in hu-
mans, M-6-G, served to link this work to a study performed previ-
ously in the same institute [197]. Finally, the synthetic peptide agonist
DAMGO was used as a reference compound. This is very common in
literature connected to the current subject, not least because it acts as
a full agonists in all three signaling pathways.
FRET-based techniques were used to study the signaling pathways
seperately in real time and in living cells. For the analysis of biased
agonism, data from work by Stefanie Mayer from the same lab were
used. Those data were acquired using a luciferase complementation
assay and compared very well to collected BRET data from this work.
Several aspects of opioid signaling as examined in this study shall
be elaborated on a little more in the following chapter. Results will be
interpreted and brought in line with relevant literature on the matter.
Also, methodological and conceptual limitations of this work will be
discussed.
The part of this work concerning the involvement of TLR4 in opioid
signaling fell rather short due to the unforeseeable dynamics inherent
to any scientific work. A few concluding remarks on the subject shall
be made nevertheless.
4.1 activation of g i by opioid ligands
The dataset at hand comprises concentration-response data for Gi ac-
tivation of 17 µ receptor ligands. Using various techniques, several
authors have reported such data over the years. Earlier studies often
relied on indirect measures of Gi activation like G protein-gated potas-
sium currents through G protein-coupled inwardly-rectifying potas-
sium (GIRK) channels [95, 198] or inhibition of cAMP accumulation
[199]. Although measurements of this kind correlate well with G pro-
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McPherson Molinari Frölich this work
DAMGO 1.04 0.91 1.01
Buprenorphine 0.55 0.65 < 1∗
Fentanyl 1.14 0.98 0.99
M-6-G 0.87 ∼ 1 0.85
Methadone 1.18 1.03
Morphine 0.98 0.73 ∼ 1 0.79
Oxycodone 0.95 0.77
Pethidine ∗ 0.86 0.98∗
Table 7: Efficacies of Gi recruitment compared to values from recent litera-
ture. ∗Curve-fitting yielded no plateau, value is extrapolated. Exter-
nal data are cited from:
McPherson et al. [201], Molinari et al. [202], Frölich et al. [197].
tein activity in general, a certain degree of signal amplification will
occur between the actual G protein activation and the measured ef-
fect. So, if one wants to know about bias between pathways, exper-
imental read-outs as close to the signaling biomolecule as possible
are advantageous. Later approaches relied on [35S]GTPγS binding
assays as a more direct measure of G protein activation [199, 200].
In brief, these assays make use of a non-hydrolyzable form of GTP,
[35S]guanosine-5’-O-(3-thio)triphosphate ([35S]GTPγS). [35S]GTPγS is
bound by an activated Gi in exchange for GDP (also see section 1.2),
after which the turnover cycle of the G protein is halted. The amount
of bound [35S]GTPγS can be determined as a measure of G protein ac-
tivation. The downside of this experimental approach is that it needs
to be done in membrane preparations of cell lysates. Therefore, the
read-out takes place outside the intact cell, which can easily lead to
distortions of the actual signaling properties.
Nevertheless, [35S]GTPγS binding data by McPherson et al. [201]
and Molinari et al. [202] represent the most recent and most com-
parable data available in the literature on the matter of G protein
activation. One exception is a piece of work by Frölich et al. [197],
who used a FRET sensor similar to the one in this work. The largest
overlap between the sets of opioids can be found with the work by
McPherson et al.. With the mentioned methodological differences and
constraints in mind, it is even more convincing to see how well in line
the values actually are. Slight differences are found for morphine and
oxycodone, which McPherson et al. classify as full agonists (Emax 0.98
and 0.95, respectively) whereas this work sees them as strong partial
agonists (Emax 0.79 and 0.77). Similarily in line are findings by Moli-
nari et al.. Frölich et al. do not provide numerical values for the effi-
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McPherson Molinari Frölich this work
EC50 logEC50 EC50 EC50 logEC50
DAMGO 11.2 −7.5 46 37.5 −7.43
Buprenorphine 14.5 −8.8 179 −6.75
Fentanyl 56.8 −8.0 38.1 −7.42
M-6-G 81.0 37 290 −6.54
Methadone 87.2 227 −6.65
Morphine 97.5 −7.8 15 412 −6.39
Oxycodone 564 1, 610 −5.79
Pethidine > 10, 000 −5.6 26, 900 −4.57
Table 8: Potencies of Gi recruitment compared to values from recent litera-
ture. Ligand concentrations are given in nM. External data are cited
from McPherson et al. [201], Molinari et al. [202], Frölich et al. [197].
cacies, but they are derived from depicted curve fits. For an overview,
see table 7.
In terms of potencies, the situation is similar. McPherson et al. gen-
erally find slightly higher potencies, but in no case (except buprenor-
phine) by more than half a log level. This may be explained by the
comparably smaller receptor reserve of the [35S]GTPγS assay com-
pared to overexpressed functional G proteins. For buprenorphine,
values diverge by a factor of 10 (EC50 14.5 nM vs. 179). In this spe-
cial case, the method used in this work might indeed be inferior.
Buprenorphine is known to have a very high binding affinity for the
µ receptor in the sub-nanomolar range (0.08 nM, [203]). In an assay
like the one used here, where after each array of measurements addi-
tion of DAMGO as a reference is necessary, this high binding affinity
might impair proper binding of DAMGO. As was pointed out in sec-
tion 3.2, the Gi activation data of Buprenorphine were not easily fitted.
The values from Molinari et al. are a little more off, yet constantly so,
by 1-1.5 log levels, buprenorphine set aside. Again, the decreased re-
ceptor reserve might serve as an explanation. As to what extent the as-
says of Molinari et al. and McPherson et al. differ in technical details
to account for the differences in their respective datasets, is beyond
the author’s knowledge. Compared to the findings of Frölich et al.,
again, in this work potencies tend to be lower (i.e. higher EC50). While
results for DAMGO match just fine (46 nM and 37.5 nM), M-6-G and
Morphine differ by a factor of 10-20. Apart from a slightly different
sensor construct, there is no obvious explanation for this.
Beyond buprenorphine, a few more ligands could not be concen-
trated high enough in order to obtain a maximum plateau signal:
pethidine, tapentadol, and tramadol. These are, by far the least po-
tent opioids used in this set of ligands and, with the exception of
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Figure 28: Scatter plot of experimentally determined potencies for Gi acti-
vation and clinical potencies from the literature (see table 1) of
several opioids. Values were normalized to morphine for better
comparability. Spearman’s ρ = 0.93, p< 0.0001. For details, see
text.
pethidine they are partial agonists in terms of Gi activation. However,
it should be mentioned that the categorization as a partial agonist is
not entirely accurate if one cannot determine the maximum signal
with certainty. It is theoretically possible that those ligands are in fact
full agonists, be it in a system/tissue with higher signal amplifica-
tion, or at even higher concentrations. In the context of this study,
labeling them partial agonists is legitimate insofar, as there are "real"
full agonists in the same assay system. Practically, this is all of little
importance, as the following example might illustrate. Tramadol, for
example, is not supposed to be dosed higher than 400 mg per day in
a patient. With its molecular weight of 263,38 g/mol this translates into
1.52 mmol tramadol per day. At an assumed blood volume of 5 l in
an adult, hematocrit of around 0.5, and even with 100% bioavailabil-
ity and a very low volume of distribution (both of which are not the
case), the highest plasma concentration possible would be approxi-
mately 0.4 mM. This is a concentration that was still within the the
tested range in this study. After all, tramadol might in theory be a
full agonist, for a pharmacology based on humans however this is of
subordinate importance. Similar considerations are true for the other
"weak" partial agonists.
Another question to be raised in the face of the data at hand might
be, to what extent the potencies with regard to activation of a G pro-
tein are correlated with those found in clinical application. As was
pointed out in the introduction, opioids are assessed by their capa-
bility to ease pain compared to morphine. Thus, if analgesic effects
were truly mediated by G protein activation first and foremost, there
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EC50 Gi activation [nM] Ki [nM]
Buprenorphine 179 0.21
Fentanyl 38.1 1.3
Hydromorphone 31.7 0.37
Methadone 227 3.4
Morphine 412 1.2
Oxycodone 1, 620 25.9
Pethidine 26, 900 450
Sufentanil 4.22 0.14
Tramadol 138, 000 12.5
Table 9: Potencies of Gi activation from this work put next to binding affini-
ties as determined by Volpe et al. [204], where available.
should be a correlation. And indeed, as figure 28 shows, when plot-
ting experimental Gi potencies and observed clinical potencies, there
is nearly perfect rank order correlation between the two. Taking into
account that the molecular event of activating a G protein and the
subjectively conceived clinical outcome of analgesia certainly are in-
fluenced by a plethora of confounders, the unambiguity of the corre-
lation is surprising. This merely serves to demonstrate that the exper-
imental data obtained in this work are of some practical value. It has
never been the intention of this work to find such correlations, nor
have data on clinical potencies of opioids been collected.
One last aspect worth discussing in the light of Gi activation is its
association with ligand-receptor binding. Data of this kind were not
collected in this study, yet a rather strong correlation is to be expected.
It is out of the question that an activated (i.e. agonist-bound) receptor
is needed to activate a G protein. Also, no activators of G proteins
other than active-state GPCRs are known. So, if the ligands of inter-
est are sufficiently selective for the µ receptor, receptor binding and
G protein activation should be closely correlated. As there is no possi-
bly amplifying instance in between receptor and G protein, it is only
the turnover rate of the active receptor (i.e. how many G proteins
one receptor can activate before it is silenced by an arrestin), which
determines the difference between binding affinity and Gi activation
potency. This is a phenomenon referred to as receptor reserve. The
crux with binding data is that they tend to differ a lot between exper-
iments in different laboratories. A recent study found affinity ranges
of as much as four log levels for a single opioid ligand in the liter-
ature [204]. However, the authors also provided affinity values from
their own experiments for many of the opioids used in the work at
hand, so those are at least internally consistent. When comparing the
experimental Gi potencies of this study with those binding affinities,
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they appear to match rather well (see table 9). Higher affinity leads
to higher potency and vice versa. The binding affinity of each ligand
is higher than its respective Gi activation potency, which is reason-
able. Aside from buprenorphine and tramadol, where potencies were
not exactly determinable, the log distance between binding affinity
and potency of every ligand varies in a narrow range between ∼ 1.5
(fentanyl) and ∼ 2 (hydromorphone) for those ligands where binding
data are available from Volpe et al. [204]. All taken together, the data
on Gi activation appear conclusive both in itself and in comparison
with previously published data.
4.2 recruitment of β-arrestins to the receptor
Recruitment of β-arr2 to the µ receptor was thoroughly looked into
in this work as a second important interaction occuring at and with
the activated receptor apart from Gi activation. Data for β-arr1 recruit-
ment were not collected in this work; however, for ensuing calculation
of ligand bias, unpublished data by Stefanie Mayer were used (also
see section 3.3). In-depth analysis will be left up to her. Only two brief
statements concerning these data shall be made: (1) For β-arr2 re-
cruitment, results from luciferase complementation experiments and
from the NanoBRET assay match well under comparable assay condi-
tions. EC50 values for any ligand were never more than one log level
apart between the two assays. One marked exception is tapentadol.
In the luciferase complementation assay it seems to be an antagonist,
whereas with NanoBRET it is a partial agonist with micromolar po-
tency. From the data available, there is no obvious explanation for
this that would go beyond speculation. For detailed results of the lu-
ciferase complementation experiments, see table 12 in the appendix.
(2) Potencies for β-arr1 recruitment were equal or lower than those for
β-arr2 throughout the set of ligands. This is in line with generally ac-
cepted previous findings, suggesting that class A GPCRs have higher
afinity for β-arr2 than 1 [86]. After all, this validates the NanoBRET
assay in comparison with a previously established assay and proves
general consistency of the findings with earlier results from the liter-
ature.
Data on β-arr2 recruitment to the µ receptor in the literature are
mainly found in those publications which already served for compar-
ison of the Gi data. It is noteworthy to say that both McPherson et al.
[201] and Molinari et al. [202] performed their experiments - enzyme
complementation (PathHunter R©) and BRET, respectively - without
overexpression of GRKs, whereas Frölich et al. [197] used a FRET
assay with overexpressed GRK2. In table 10, efficacies for β-arr2 re-
cruitment from the literature are put next to respective findings from
this work. The findings are in excellent accordance to those by Moli-
nari et al. [202]. Generally, the same is true for McPherson et al. [201],
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McPherson Molinari Frölich this work
DAMGO 1.24 0.89 1 0.97
Buprenorphine 0 0.02 0.0
Fentanyl 0.89 0.77 0.73
Methadone 1.14 0.80
Morphine 0.19 0.24 approx. 0.7 0.28
Oxycodone 0.18 0.05
Pethidine 0 0.41∗ 0.21∗
Table 10: Efficacies of β-arr2 recruitment compared to values from recent
literature. ∗Curve-fitting yielded no plateau, value is extrapolated.
External data are cited from:
McPherson et al. [201], Molinari et al. [202], Frölich et al. [197].
although it needs to be mentioned that they used alfentanil instead
of DAMGO as a reference compound (unlike for their Gi data). This
makes DAMGO a superagonist with an Emax of 1.24, suggesting that,
when normalizing to DAMGO instead, the indicated values would
possibly be a bit lower and then match this work’s finding very well,
too. The two values from Frölich et al. [197] are not explicitly indi-
cated in their work, but can be estimated from graphs. Therefore,
detailed comparisons are out of the question.
When looking into potencies, the situation is rather similar. Com-
pared to Molinari et al. [202], EC50 values are never off by more than
half a log level. The same is essentially true for data by McPherson
et al. [201]. When comparing the data to Frölich et al. [197], one has
to bear in mind that they co-transfected GRK2 for their β-arr FRET
experiments. Instead of the values indicated in table 11, it would be
more appropriate to compare their data to those from this work ob-
tained with GRK2 overexpression as well (DAMGO: 106 nM, mor-
phine: 390 nM). When doing so, again the data correspond just fine.
Additionally, there are data on DAMGO and morphine by Nickolls
et al. [205], also acquired using the PathHunter R© system. Again,
logEC50 values are in close-to-perfect accordance (DAMGO: -6.11,
morphine: -6.33).
Another aspect worth looking into is how β-arr recruitment be-
haves compared to Gi activation. The following attracts attention: (1)
The efficacy of any opioid is generally lower for β-arr2 recruitment
than for Gi activation. Most straightforward, this can be seen from
the fact that there are no full agonists in terms of β-arr2 recruitment
in this set of ligands, whereas there are several with regard to Gi ac-
tivation (fentanyl, L-methadone, pethidine, piritramide, remifentanil,
sufentanil). Most of the Gi partial agonists are weaker β-arr partial
agonists, some others turn into antagonists altogether, like tramadol
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McPherson Molinari Frölich this work
EC50 logEC50 EC50 EC50 logEC50
DAMGO 414 −6.7 60 749 −6.13
Buprenorphine n/a −7.2 n/a n/a
Fentanyl 210 −6.6 96.4 −7.02
Methadone 2110 886 −6.05
Morphine 322 −6.4 457 632 −6.20
Oxycodone 1460 3, 090 −5.51
Pethidine n/a −3.2 393, 000 −3.41
Table 11: Potencies of β-arr2 recruitment compared to values from recent
literature. Ligand concentrations are given in nM. External data
are cited from:
McPherson et al. [201], Molinari et al. [202], Frölich et al. [197].
and buprenorphine (depending on the efficacy one regards as the
minimum a ligand needs to have not to be an agonist in the first place,
this could also be the case for hydromorphone, oxycodone, and pir-
itramide). For potencies, things look similar. Overall, Gi activation is
left-shifted compared to β-arr recruitment, from as little as 1.5 times
(morphine) to around 60 times (remifentanil). The exception to prove
the rule is piritramide with a right-shift by a factor of 2. The general
finding of left-shifted Gi potencies does probably not have any direct
implications on how GPCRs signal. In a classical receptor activation
model with Gi as the active signal and β-arr as the limiting factor, it
certainly makes sense to not have the signal terminated before it be-
gins (as would be the case with a marked right-shift). However, taking
into account that β-arrs are signaling proteins in their own right, such
a situation is possible. After all, this leads to considerations on biased
agonism and shall be discussed there (section 4.3).
4.3 biased agonism and the role of grk2
While the concept of biased agonism or functional selectivity has only
emerged during the last couple of years, findings which - in retrospect
- hint towards such a phenomenon were reported earlier. In vivo stud-
ies in guinea pigs’ ilea showed functional activation of the µ receptor
but no endocytosis of the receptor by morphine [206]. Keith et al.
[207] found similar results in HEK-293 cells. From such rather de-
scriptive findings the evidence grew slightly more mechanistic over
the years. In 1998, Zhang et al. [96] showed that morphine as op-
posed to other opioids does not phosphorylate the µ receptor, neither
does it recruit β-arr to the receptor in confocal imaging. The miss-
ing β-arr recruitment by morphine was also described by Whistler
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and von Zastrow [101] in the same year. Even more sophisticated
were results by Bohn et al. [208] in 2004. They showed that, while
morphine and heroin recruit β-arr to the µ receptor only to a minor
extent, fentanyl and methadone are very successful in doing so in
confocal imaging. Moreover, they could show in animal studies that
morphine and heroin induced prolonged analgesia in β-arr2 knock-
out mice, whereas fentanyl, methadone, and etorphine do not present
with an altered phenotype. They hypothesized the missing ability
of morphine and heroin to also recruit β-arr1 to the receptor dimin-
ishes receptor desensitization and therefore extends the analgesic ef-
fect. The more efficacious agonists were also able to recruit β-arr1 as
proven by confocal microscopy and therefore induce normal receptor
internalization even in β-arr1 knock-out mice.
When it comes to looking into actual ligand bias, there are mainly
three studies in the literature which are comparable to this work in
terms of methodology. Two of them - McPherson et al. [201] and Moli-
nari et al. [202] - have been extensively cited in previous sections
of this dicussion. The most recent (and most alike) work is one by
Thompson et al. [209], which compared several signaling pathways at
the µ receptor with regard to endogenous opioid peptides. Whereas
this last work is even compatible with the one at hand in terms of the
method for bias quantification, the first two are not. Molinari et al.
[202] do not engage in any systematic bias quantification, at all. The
focus of their work was mainly on a comparison between opioid ac-
tivities at the µ and δ opioid receptor subtypes. In general, they state
that there are ligands with Gi activity and no β-arr recruitment but
not the other way around. This supports the findings of this present
work, where the same stands true. However, this should not be too
surprinsing, as it is hardly imaginable how a putative µ receptor ag-
onist without intrinsic activity for Gi activation would induce analge-
sia. When they go into details about the Gi-β-arr signaling dichotomy,
they do so by comparison of intrinsic activities. The one compound
they find noteworthy which also appears in this work’s set of lig-
ands is buprenorphine. They do not find any β-arr2 recruitment but
partial agonism for Gi activation. In such an extreme case, where on
pathway is completely neglected by a ligand, it is probably fair to
call that ligand biased - this work does so, too. However, it should
be noted that merely comparing intrinsic activities can only provide
qualitative statements on ligand bias. For example, a ligand acting
as a partial agonist in two pathways cannot be assesed properly with
this method, as neither receptor density in the tissue nor signal ampli-
fication are accounted for in such a model. Still, small as the overlap
between their work and this one may be in this case, the findings on
buprenorphine coincide.
The work by McPherson et al. [201] goes one step further. Besides
Gi activation determined by [35S]GTPγS binding and β-arr recruti-
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ment (BRET) they also investigated receptor internalization as a dis-
tinct signaling pathway. This work refrained from doing likewise, as
the aforementioned unpublished work by Stefanie Mayer will elabo-
rate on that. As for Gi and β-arr signaling, the authors simply cor-
relate efficacies. However, they do so using the operational efficacy
parameter τ rather than EC50. This rids the data from confounders
like receptor density, even more so as dedicated binding experiments
were performed. From their correlations they find endomorphins 1
and 2 to be slightly biased towards β-arr; neither of the compounds
were used in this work. From the substances this work identified as
biased, only buprenorphine is also in the set of ligands in the study
of McPherson et al. [201]. They do not report it as biased explicitely,
but mainly so because the lack of β-arr response - just like in this
work - renders determination of an operational efficacy impossible.
In principle, their finding is congruent with the one in the study at
hand.
All which goes beyond the indicated overlap with data from the lit-
erature constitutes entirely new knowledge in the field of molecular
µ receptor pharmacology. For the first time, a broad range of opioid
ligands in everyday clinical use were subject to a structured analy-
sis and quantification of possible ligand bias. It showed some refined
bias towards β-arr2 (sufentanil) and towards Gi (remifentanil), both
of which could only be detected with the use of operational model rel-
ative intrinsic efficacy comparison. More unambiguous results were
found for buprenorphine, tapentadol, tilidine, and tramadol. None
of these ligands recruited any β-arr to the receptor, yet all were Gi
agonists to some extent.
Yet, probably the most striking findings arose when, additionally,
expression levels of GRK2 were changed. G protein-coupled receptor
kinases phosphorylate GPCRs in an agonist-dependent manner, in
the case of the µ receptor, GRK2 is of particular importance (see sec-
tion 1.2). In this work, plenty of detailed concentration-response data
are available that allow for analysis of the influence GRK2 expres-
sion has on β-arr recruitment. The β-arr experiments discussed so far
were all performed in HEK-293 cells with their "natural" GRK2 back-
ground. When GRK2 was overexpressed in addition to the µ receptor
and β-arr, recruitment of the latter was drastically enhanced through-
out all ligands. Certainly, this was to be expected when considering
reports in the literature. As pointed out, overexpression of GRK2 was
previously found to boost β-arr recruitment elicited by morphine
[96, 101, 102]. More recently, these findings were further refined. It
appears as if phosphorylation of the C-terminal tail of the µ receptor
was a sequential and hierarchical process, i.e. Ser375 is the first and
most important site to be phosphorylated. Subsequently, more
residues will be phosphorylated in an agonist-dependent manner.
At the µ receptor, this was shown to affect receptor desensitization
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[154] as well as internalization [210]. This adds an entirely new di-
mension to the concept of bias, because now, between Gi activation
and β-arr recruitment, there is another signaling process which has
distinct influence on the overall signaling pattern. At the β2-AR, this
"phosphorylation barcode" was shown to even induce different β-arr2
conformations with different signaling outcomes [105]. Thus, it is rea-
sonable to believe that similar mechanisms exist at the µ receptor as
well.
Nonetheless, receptor phosphorylation and GRK expression have
so far not been thoroughly investigated with regard to biased ag-
onism. McPherson et al. [201] did assess receptor phosphorylation,
but only at Ser375 and only with endogenous GRK expression. Only
very recently, a study driven by the pharmaceutical industry tried a
first systematic approach at the matter by using a baculovirus system
for GRK2 transfection/infection and gradually adapting the multi-
plicity of infection [211]. The authors disclosed detailed results only
for DAMGO and morphine, but so far, their findings speak the same
language as this work does. For DAMGO, they report an Emax of 0.95
and EC50 of 160 nM (this work: 0.97 and 749 nM) with endogenous
GRK2 expression. When inducing maximum GRK2 overexpression
(multiplicity of infection = 50), the pharmacology changes as follows:
Emax=1.10, EC50=6.8 nM (this work: 0.98, 106 nM). There is a simi-
lar situation for morphine. Without GRK2 overexpression: Emax=0.27,
EC50=240 nM (this work: 0.28, 632 nM); with GRK2 overexpression:
Emax=0.96, EC50=17 nM (this work: 0.83, 390 nM). Moreover, they
could not detect a β-arr signal induced by buprenorphine without the
contransfection of GRK2. When overexpressing the kinase, however,
they see a signal and can calculate a ∆∆log(τ/KA) value of around
1.25 (this work: no buprenorphine signal with GRK2 overexpression,
bias estimated at ∆∆log(τ/KA) ∼ 1). Taking into account basic ex-
perimental differences (U2OS cells instead of HEK-293, virus infec-
tion instead of lipid transfection), differences between the findings
are minimal.
Returning to this work’s findings on GRK2 overexpression, the
changes in β-arr recruitment were profound (see section 3.6). On top
of this, all significant ligand bias was diminished except for buprenor-
phine (see section 3.8). These findings are of particular importance,
as most of the research on biased ligands at the µ receptor these
days aims towards identifying Gi biased ligands, i.e. agonists that
do not recruit β-arrs. This is based on findings in knock-out mice,
where morphine analgesia was improved [173]. Furthermore, the use
of β-arr small interfering RNA enhanced analgesia and reduced tol-
erance to morphine in mice and rats [212, 213]. Also, respiratory de-
pression and constipation were attenuated in β-arr knock-out mice
[45, 174]. Subsequently, a first Gi biased µ receptor ligand, herkinorin,
was reported in 2007 [214], which did not recruit β-arr and therefore
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did not induce receptor internalization. Further research led to the
discovery of TRV130, a novel µ receptor Gi biased agonist with anal-
getic potency comparable to morphine but attenuated gastrointesti-
nal and respiratory side-effects in animals [175] and humans [215].
So far, however, the respective expression of GRK2 was left to chance
in the experiments assessing biased µ receptor ligand. With the data
at hand, it seems like the influence of GRK2 on the important β-arr
recruitment outcome is too substantial for further studies not to con-
trol its expression. As a consequence, when screening for Gi-biased
ligands like in the study put forward by Winpenny et al., general over-
expression of GRK2 may be advisable in order to specifically identify
structures of the likes of buprenorphine rather than, say, tramadol.
There is no reason to believe that GRK2 levels in any physiological
target tissue are somehow foreseeable, so a potential new drug has
to be able to remain biased under all circumstances; even more so,
as evidence exists for morphine-induced GRK2 up-regulation in rat
brains in vivo [216]. The fact that Winpenny et al. did actually find a
buprenorphine response when overexpressing the kinase might just
as well be due to the design of the pharmaceutical industry’s high-
throughput screening assays. Usually, these assays aim at very high
sensitivity at the cost of specificity, and understandably so, as missing
a potential hit would be way more expensive than erroneously select-
ing a few false-positives. In the experience of the lab this present
work was carried out in, the PathHunter R© assay used in the study by
Winpenny et al. tends to behave in this very manner, especially with
weak partial agonists (experimental data to prove this valuation are
not given).
The successful development of TVR130 as an intentionally designed
biased agonist spurred further research in the field. One recent work
made an effort to elucidate the value of Gi bias in even greater detail.
Schmid et al. [217] could conclusively show that the degree of ligand
bias has a quantitative effect on the presumed safety of an opioid
drug. In their work, the researchers developed an array of µ receptor
agonists with distinct degrees of Gi bias by changing the substituents
at a piperidine core structure. Over a series of in vitro and in vivo ex-
periments in mice, these newly designed compounds were found to
cause less and less respiratory depression when Gi bias was enhanced
while maintaining reliable analgesic potency. Thus, optimizing com-
pounds for the greatest possible ligand bias might become a key goal
in future pharmaceutical research.
4.4 tlr4 and opioids
When basic concepts of the research work at hand were thought up in
2012, the report by Hutchinson et al. [189] claiming activity of opioid
ligands at the TLR4 (also see figure 1.6) was rather new. It was reason-
4.4 tlr4 and opioids 81
able to try to investigate action profiles of opioids at the µ receptor
and TLR4 simultaneously. To start with, one tried to replicate basic
findings for said study in the same reporter gene cell line (HEK-Blue
hTLR4).
As the presented results in this work (section 3.10) indicate, it was
not possible to reconstruct these prior findings. None of the opioids
used in this work elicited substantial TLR4 response in HEK-Blue
hTLR4 experiments. This discrepancy can probably be ascribed to
two factors: (1) As opposed to Hutchinson et al. [189], great care was
taken to diminish any contamination of tested opioids with endotox-
ins in this work. There is no mention of such measures in the refer-
enced study. Thus, it is possible that, in part, their signals stem from
endotoxin contamination. As was pointed out, endotoxin (or LPS) is
part of of the cell wall of gram-negative bacteria, of which many gen-
era are found physiologically on and in all humans (e.g. Neisseria).
(2) In the experiments presented in this work, opioid-induced TLR4
responses were normalized to a maximum LPS signal and merely
corrected for the baseline signal elicited by sterile water. However,
Hutchinson et al. [189] used this baseline signal as a reference and
normalized all responses to it. This procedure is suited to inflate the
measured responses. Still, if statistical evaluation was done properly
(which has to be assumed), the corresponding errors would be in-
flated in a similar manner. Thus, if the authors report statistically
significant responses of opioids over a baseline signal - which they
do - this has to be appreciated.
Moreover, there are still remarkable findings in vivo that remain un-
affected by possible methodological shortcomings of the HEK-Blue as-
say. Apart from the mentioned effects of TLR4 as a functional "antag-
onist" of opioid signaling [189] and - the other way around - reports
that presumed inactive morphine metabolites enhance pain via TLR4
[187], the receptor was also found to play a role in opioid dependence.
Interestingly, the opioid antagonists naloxone and naltrexone were
found to counteract opioid-induced conditioned place preference, a
behavioral test for dependence, and reduced self-administration of
remifentanil in rats [218]. This is even more compelling, as the antago-
nists exerted their effects non-stereoselectively, which would allow for
the (+)-isomers to be used as TLR4 modulators without affecting the
(-)-selective opioid receptors. This situation, where results in animal
studies can not readily be transferred to simplified cell-based assays
calls for more sophisticated mechanistic explanations. And indeed,
in silico docking studies and in vitro biochemical experiments seem
to show that naloxone, naltrexone, and remifentanil can bind to the
TLR4-MD2 complex [218, 219]. The involvement of the co-receptor,
MD2, might be one reason for the complexity of the interrelationship
of opioids and TLR4 signaling. Another one is that both (+)-naloxone
and (+)-naltrexone selectively blocked the TRIF-dependent interferon
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I signaling pathway of TLR4, but not MyD88-dependent NF-κB sig-
naling [219] (also see figure 7), much in the sense of biased agonism.
In conclusion, the matter can be summed up as follows: Early find-
ings of opioids activating TLR4 could not be reproduced, neither in
this work, nor by another laboratory [191]. The authors of the initial
study acknowledge this fact in a way [220] and consider the used as-
say not entirely suited for the purpose but, quite rightly so, refer to in
vivo effects as well as in silico and in vitro hints towards direct binding
of opioids to TLR4. At this point, TLR4 antagonism by (+)-isomers
of naloxone or naltrexone as lead structures seems to be the most
compelling possible application. Future research will need to eluci-
date the actual molecular mechanisms at the receptor by means of
high resolution live-cell assays and resolving of opioid-bound TLR4
structures, even though driving forces in the field appear to be more
interested in possible clinical applications.
4.5 limitations and outlook
In the research work at hand, great care was taken to choose appropri-
ate assays for the respective purposes. However, when weighing up
the pros and cons in each situation, there often is no single best assay
to choose. In what follows, some limitations of the methods deployed
in this work shall be discussed.
4.5.1 FRET experiments for Gi activation
The process of Gi activation has its "morphological" correlate in the
movement of protein subunits relative to each other in the range of
only several nanometers. It is obvious that such movements cannot
be detected by means of classic light microscopy due to diffraction
limitations. If, additionally, one wants to portray the process in a dy-
namic fashion, tools like electron or atomic force microscopy are out
of the question as they require fixed samples. FRET constitutes a rea-
sonable choice because it meets all the criteria. It can be done in living
cells and also yields kinetic information at a millisecond resolution.
Some arising limitations are more due to the specifics of the research
subject than to the method as such. In this special case where the G
protein consists of three separately encoded subunits in addition to
the required receptor, one has to deal with four plasmids for transient
transfections. This was done in the literature before [197], but when
trying to replicate the experimental setup in this work, signal quality
was found to be rather poor. Stable transfections would not critically
improve the situation, as quadruple-stable cell lines are viable but not
easily maintained. The most promising approach seemed to be the im-
plementation of a single-plasmid Gi version with fixed stoichiometric
ratios of the subunits [221]. This led to drastically improved signal-
4.5 limitations and outlook 83
to-noise ratios and greatly enhanced the experimenter’s chances to
investigate a cell containing all the required components in this single-
cell approach. Further improvements could have been stable transfec-
tion of the remaining two plasmids (receptor and Gi trimer) or also
tagging the receptor with a fluorescent dye for monitoring transfec-
tion success. This could be put into effect using a viral 2A peptide,
which would be cleaved after translation. By this means, the fluo-
rophore would not permanently stay attached to the receptor and
possibly interfere with the measurement, yet its mere existence in the
cytosol would prove successful expression of the receptor.
Generally, if one does not make use of the high temporal resolu-
tion, a more high throughput-compatible approach would be desir-
able. So far, ratiometric FRET experiments in microtiter plate readers
have been implemented with only very limited success. This is most
likely accounted for by the relatively high background signal in FRET
experiments due to the need of an external light source and the of-
ten rather low quantum yield of the fluorophore pairs in combina-
tion with limited sensitivity and specificity of the photomultipliers.
A valid alternative could be BRET, which, to the author’s knowledge,
has so far not been used in the context of G protein activation. An-
other problem with flourescence-based methods could arise from the
unarguably large space the fluorophores take up. One way out would
be the use of small-molecule fluorophores such as FlAsH, possibly at
the cost of reduced quantum yield. In the present work however, this
did not seem to be a problem as the results corresponded to findings
from the literature very well (see section 4.1). After all, determining G
protein activation by FRET is probably as good as it gets with regard
to accuracy and temporal resolution.
4.5.2 BRET experiments for β-arrestin recruitment
The recruitment of β-arr2 to the µ receptor was investigated using a
BRET approach in this work. Many general considerations are similar
to what was said about FRET in section 4.5.1. It was chosen because
it allows for dynamic studies of the interaction process in living cells.
Moreover and in contrast to single-cell FRET, it is easily implemented
in a microtiter format and thus data acquisition is more efficient. One
reason which stood against the use of BRET for Gi activation exper-
iments was the fast kinetics of the process under investigation. With
β-arr recruitment, this is no major concern as it takes more than a
minute for the interaction to occur. Such kinetics can be covered with-
out any problems on usual microtiter plate-readers.
As a possible pitfall, again, the need for fusing a fluorophore to
the proteins in question comes into consideration. However, fusion
proteins with a GPCR or a β-arr at either terminus are rather standard
constructs in the field. Again, the data collected in this work are very
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well in line with previously published findings (see section 4.2). Even
though in this work, the β-arr was actually fused to a HaloTag rather
than the actual fluorophore, this does not argue much in favor of the
technique in terms of this very issue as the tag and most fluorophores
are comparable in size. Lastly, BRET depends on the presence of a
substrate as opposed to FRET. From our results and the comparison
with earlier data, there was no reason to believe that the presence of
the luciferase substrate interfered with the protein interaction in any
way.
4.5.3 Analysis of agonism bias
Experiments in this work were carefully designed in order to allow
for in-depth analysis with respect to possible ligand bias using the
operational model of agonist activity. Detailed characteristics of the
applied approach are described in section 1.5. While the approach
chosen in this work can be considered the agreed-upon best standard
for agonism bias analysis, it has its limitations with very low potency
agonists or antagonists. When a ligand’s potency in one signalling
pathway approaches zero, further calculations are rendered impossi-
ble. Recently, modifications to the operational model were proposed.
Herein, the pharmacodynamics of partial agonists are evaluated more
precisely in a competition assay against a reference full agonist [222].
This competitive model would have required additional experiments
but might have helped to actually calculate bias values for ligands
like buprenorphine rather than simply make estimations based on
the apparently missing efficacy in the β-arr assays.
4.5.4 Reporter gene assay for TLR4 activation
General and fundamental problems with the HEK-Blue assay as a
tool for determining TLR4 activation other than through LPS have
been laid out in section 4.4. In brief, the most important concerns
are: (1) NF-κB, which is the pivotal point in the assay as it controls
the promotor for the synthesis of SEAP, is only one of several signal-
ing endpoints downstream of TLR4. Even though both major path-
ways (MyD88 and TRIF, see figure 7) lead to the production of NF-κB,
there are constellations where it is mostly unaffected [219]. (2) Very
much unlike in the oversimplified schematic that is figure 7, a myr-
iad of signaling and adaptor proteins is necessary between receptor
activation and NF-κB. Many of those intermediste steps also repre-
sent intersection points with other, TLR4-unrelated pathways. This
means one uses a very far downstream read-out for the detection of
a membrane-bound receptor’s activation. In conclusion, the experi-
ments performed in this work were reasonable at the time, but in
hindsight merely reproduced the now generally accepted finding in
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the field that the used assay is not too well suited for experiments on
TLR4 activation by opioids. Direct measures of ligand-receptor inter-
action or at least activation and recruitment of very early adaptor pro-
teins are needed in future studies to clarify the actual opioid-related
processes at toll-like receptors.
4.5.5 Outlook
This work provides information about the properties of a wide range
of clinically deployed opioids in unprecedented detail with regard to
Gi activation and β-arr recruitment to the µ receptor. These very fun-
damental findings will serve as a basis and reference for future stud-
ies on the subject. Future research will have to focus on the translation
of these findings into even more physiological experimental systems,
i.e. animal models and humans, as pain is a rather complex and sub-
jective phenomenon which cannot be fully appreciated in isolated cell
lines. This is even more true for the role of TLR4 in the development
of pain and opioid-related side effects. Additionally, more attention
will need to be paid to the involvement of GRKs. Maybe some of the
features that are today attributed to β-arr are in reality GRK effects
with β-arr being the first downstream signal of GRK. For such ques-
tions and many more, the present work poses a solid foundation.

5
S U M M A RY
5.1 english
To this day, opioids represent the most effective class of drugs for the
treatment of severe pain. On a molecular level, all opioids in use to-
day are agonists at the µ-opioid receptor (µ receptor). The µ receptor
is a class A G protein-coupled receptor (GPCR). GPCRs are among
the biological structures most frequently targeted by pharmaceuticals.
They are membrane bound receptors, which confer their signals into
the cell primarily by activating a variety of GTPases called G pro-
teins. In the course of the signaling process, the µ receptor will be
phosphorylated by GRKs, increasing its affinity for another entity of
signaling proteins called β-arrestins (β-arrs). The binding of a β-arr
to the activated µ receptor will end the G protein signal and cause
the receptor to be internalized into the cell. Past research showed that
the µ receptor’s G protein signal puts into effect the desired pain re-
lieving properties of opioid drugs, whereas β-arr recruitment is more
often linked to adverse effects like obstipation, tolerance, and respi-
ratory depression. Recent work in academic and industrial research
picked up on these findings and looked into the possibility of enhanc-
ing G protein signaling while suppressing β-arr recruitment. The con-
ceptual groundwork of such approaches is the phenomenon of biased
agonism. It appreciates the fact that different ligands can change the
relative contribution of any given pathway to the overall downstream
signaling, thus enabling not only receptor-specific but even pathway-
specific signaling.
This work examined the ability of a variety of common opioid drugs
to specifically activate the different signaling pathways and quantify
it by means of resonance energy transfer and protein complemen-
tation experiments in living cells. Phosphorylation of the activated
receptor is a central step in the canonical GPCR signaling process.
Therefore, in a second step, expression levels of the phosphorylating
GRKs were enhanced in search for possible effects on receptor signal-
ing and ligand bias.
In short, detailed pharmacological profiles of 17 opioid ligands were
recorded. Comparison with known clinical properties of the com-
pounds showed robust correlation of G protein activation efficacy and
analgesic potency. Ligand bias (i.e. significant preference of any path-
way over another by a given agonist) was found for a number of
opioids in native HEK293 cells overexpressing µ receptor and β-arrs.
Furthermore, overexpression of GRK2 was shown to fundamentally
87
88 summary
change β-arr pharmacodynamics of nearly all opioids. As a conse-
quence, any ligand bias as detected earlier was abolished with GRK2
overexpression, with the exception of buprenorhin. In summary, the
following key findings stand out: (1) Common opioid drugs exert bi-
ased agonism at the µ receptor to a small extent. (2) Ligand bias is
influenced by expression levels of GRK2, which may vary between
individuals, target tissues or even over time. (3) One of the opioids,
buprenorhin, did not change its signaling properties with the overex-
pression of GRK2. This might serve as a starting point for the devel-
opment of new opioids which could lack the ability of β-arr recruit-
ment altogether and thus might help reduce adverse side effects in
the treatment of severe pain.
5.2 deutsch
Nach wie vor stellen Opioide die wirkstärkste Gruppe von Medika-
menten zu Behandlung starker Schmerzen dar. Auf molekularer Ebe-
ne sind alle heute gebräuchlichen Opioide Agonisten am μ-Opioid-
rezeptor. Der μ-Opioidrezeptor ist ein G-Protein-gekoppelter Rezep-
tor (GPCR) der Klasse A. GPCR zählen zu den häufigsten Zielstruk-
turen von Pharmaka. Sie sind membranständige Rezeptoren, die ihr
Signal in erster Linie durch die Aktivierung von G-Proteine genann-
ten GTPasen in die Zelle weiterleiten. Im Laufe des Signalprozesses
wird der GPCR von GRK phosphoryliert, wodurch seine Affinität zu
einer weiteren Gruppe von Signalproteinen, den sog. β-Arrestinen er-
höht wird. Bindet ein β-Arrestin an den Rezeptor, beendet dies das
G-Proteinsignal und veranlasst die Internalisierung des Rezeptors
ins Zellinnere. Bisherige Forschung zeigte, dass das G-Proteinsignal
des μ-Opioidrezeptors die erwünschte Schmerzlinderung vermittelt,
wohingegen die Rekrutierung von β-Arrestin oftmals mit unerwün-
schten Wirkungen wie Obstipation, Toleranzentwicklung und Atemde-
pression in Verbindung gebracht wird. Neuere akademische und in-
dustrielle Forschung griff diese Erkenntnisse auf und erkundete die
Möglichkeit, das G-Proteinsignal zu verstärken und zur gleichen Zeit
die β-Arrestinrekrutierung zu inhibieren. Die theoretische Grundlage
solcher Ansätze liegt im Konzept des biased agonism. Dieses berück-
sichtigt die Tatsache, dass verschiedene Liganden den Anteil eines
bestimmten Signalweges am gesamten vom Rezeptor ausgehenden
Signals beeinflussen kann und damit nicht nur rezeptor-, sondern
sogar signalwegspezifische Signale möglich sein sollten.
Die vorliegende Arbeit untersuchte eine Reihe von gängigen Opi-
oiden auf ihre Fähigkeit hin, die einzelnen Signalwege spezifisch zu
aktivieren und quantifizierte dies mit Methoden des Resonanzenergie-
transfers sowie der Proteinkomplementierung in lebenden Zellen. Die
Phosphorylierung des Rezeptors ist ein zentrales Ereignis in der an-
erkannten Abfolge der Signalprozesse an GPCR. Daher wurde in
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einem weiteren Schritt die Expression der phosphorylierenden GRK
erhöht und nach möglichen Auswirkungen auf die Selektivität der
Signalwegaktivierung gesucht. Hierbei wurde detaillierte pharmakol-
ogische Profile von 17 Opioiden erstellt. Der Abgleich mit bekannten
klinischen Wirkeigenschaften der Substanzen zeigte einen robusten
Zusammenhang zwischen der Fähigkeit, G-Proteine zu aktivieren und
der analgetischen Wirkstärke. Ligand bias, d.h. die signifikante Bevorzu-
gung eines Signalweges gegenüber einem anderen durch einen Ligan-
den, konnte für eine Reihe von Opioiden in lebenden HEK293-Zellen
gezeigt werden, die den μ-Opioidrezeptor sowie β-Arrestine überex-
primierten. Darüber hinaus konnte gezeigt werden, dass die zusät-
zliche Überexpression von GRK2 die pharmakodynamischen Eigen-
schaften nahezu aller Opioide grundlegend veränderte. In der Folge
war jeder zuvor gezeigte ligand bias mit Ausnahme von Buprenorphin
aufgehoben.
Zusammenfassend stehen die folgenden drei Erkenntnisse im Vorder-
grund: (1) Gängige Opioide zeigen in einem gewissen Maß Selektiv-
ität zwischen den Signalwegen. (2) Ligand bias wird beeinflusst von
GRK2-Expressionsleveln, welche zwischen Individuen, verschiedenen
Gewebetypen oder auch im zeitlichen Verlauf variieren können. (3)
Als einziges der untersuchten Opioide änderte Buprenorphin seine
Signaleigenschaften durch die Überexpression von GRK2 nicht. Dies
könnte als Anknüpfungspunkt in der Entwicklung neuer Opioide
dienen, die keinerlei β-Arrestinrekrutierung bewirken und dadurch
helfen könnten, unerwünschte Wirkungen in der Behandlung starker
Schmerzen zu verhindern.
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a.1 chemical structures of opioid ligands
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Figure 29: Structural formulae of opium alkaloids used in this work
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Figure 30: Structural formulae of semi-synthetic alkaloid derivatives used in
this work
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Figure 31: Structural formulae of synthetic opioids used in this work:
Anilidopiperidines
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Figure 32: Structural formulae of synthetic opioids used in this work:
Diphenylpropylamine derivatives
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Figure 33: Structural formula of synthetic opioids used in this work:
Phenylpiperidines
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Figure 34: Structural formulae of synthetic opioids used in this work:
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Figure 35: Structural formula of synthetic peptide opioids used in this work:
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Figure 36: Structural formulae of synthetic opioids used in this work:
Antagonists
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a.2 β-arrestin 1 and 2 recruitment to the µ receptor
(luciferase complementation)
As pointed out previously, the data on β-arr 1 and 2 recruitment as
determined by luciferase complementation are part of a separate, still
unpublished work by Stefanie Meyer. The following table 12 shall
hereby explicitly be declared a citation of the aforementioned unpub-
lished work.
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β-arrestin1 recruitment β-arrestin2 recruitment
Emax EC50 logEC50 Emax EC50 logEC50
(S.E.M.) [nM] (S.E.M.) (S.E.M.) [nM] (S.E.M.)
DAMGO
0.99 9, 150 −5.04 1.01 3, 630 −5.44
(0.16) (0.36) (0.08) (0.18)
Buprenorphine
0.0 − − 0.0 − −
(−) − − −
Fentanyl
0.53 856 −6.07 0.53 400 −6.40
(0.06) (0.13) (0.06) (0.19)
Hydromorphone
0.05 70.0 −7.16 0.19 384 −6.42
(0.01) (0.21) (0.02) (0.14)
M6G #
0.26 8, 480 −5.07
(0.64) (1.89)
Methadone
0.65 5, 030 −5.30 0.75 5, 240 −5.28
(0.07) (0.15) (0.07) (0.16)
Morphine
0.12 9, 830 −5.01 0.23 3, 080 −5.51
(0.07) (0.54) (0.02) (0.12)
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β-arrestin1 recruitment β-arrestin2 recruitment
Emax EC50 logEC50 Emax EC50 logEC50
(S.E.M.) [nM] (S.E.M.) (S.E.M.) [nM] (S.E.M.)
Naloxone
0.0 − − 0.0 − −
− − − −
Naltrexone
0.0 − − 0.0 − −
− − − −
Oxycodone
0.06 24, 800 −4.61 0.20 19, 200 −4.72
(0.01) (0.18) (0.02) (0.14)
Pethidine
0.10 251, 000 −3.60 0.22 257, 000 −3.59
(0.01) (0.19) (0.02) (0.14)
Piritramide
0.34 18, 800 −4.37 0.43 3, 470 −5.46
(0.05) (0.28) (0.04) (0.15)
Remifentanil
0.74 1, 020 −5.99 0.87 1, 080 −5.97
(0.17) (0.44) (0.10) (0.21)
Sufentanil
0.55 89.1 −7.05 0.70 37.4 −7.43
(0.14) (0.25) (0.10) (0.18)
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β-arrestin1 recruitment β-arrestin2 recruitment
Emax EC50 logEC50 Emax EC50 logEC50
(S.E.M.) [nM] (S.E.M.) (S.E.M.) [nM] (S.E.M.)
Tapentadol
0.0 − − 0.0 − −
− − − −
Tilidine
0.0 − − 0.0 − −
− − − −
Tramadol
0.0 − − 0.0 − −
− − − −
Table 12: Pharmacological properties of 17 opioid ligands for β-arrestin 1 and 2 recruitment. Data stem from luciferase complementation experiments,
GRK2 was not overexpressed in the cells. # no data acquired due to ligand supply shortages.
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a.3 bias plots
a.3.1 Luciferase Complementation
The following figure 37 shows all ∆∆ log(τ/KA) values from the cal-
culations of biased agonism with FRET Gi and luciferase complemen-
tation β-arr data. This figure is in part shown in section 3.7 (figure 23)
DA
MG
O
Bu
pre
no
rph
ine
Fe
nta
nyl
Hy
dro
mo
rph
on
e
M6
G
Me
tha
do
ne
Mo
rph
ine
Ox
yco
do
ne
Pe
thid
ine
Pir
itra
mid
e
Re
mif
ent
ani
l
Su
fen
tan
il
Tap
ent
ad
ol
Tili
din
e
Tra
ma
do
l
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
6 Gi - β-Arr1
Gi - β-Arr2
β-Arr1 - β-Arr2
Δ
Δ
lo
g 
(τ
/K
A) * * * *
Figure 37: Bias plot of all opioid agonists. Bias was calculated based on
FRET Gi data and β-arr recruitment data from luciferase comple-
mentation. Positive ∆∆ log (τ/KA) values indicate bias towards
the signalling pathway named first in the respective legend, and
vice versa. Error bars denote 95% CI. Values marked with an as-
terisk (*) are arbitrarily assigned to 1. Here, bias could not be
calculated due to missing activity in both β-arr pathways.
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